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Coronary heart disease (CHD) is a major public health problem in western countries as it 
continues to be a leading cause of premature mortality and morbidity. Several risk factors 
contribute to CHD risk, including dyslipidemia with low high density lipoprotein cholesterol 
(HDL-C) and high low density lipoprotein cholesterol (LDL-C). Meta analysis of genome wide 
linkage analysis in families with diverse ethnicity has revealed a strong linkage with different 
lipid traits on chromosome 19q13.2. There are several candidate genes present under this linkage 
region, including APOE/C1/C4/C2 gene cluster. With the exception of APOE, other genes in this 
cluster have not been extensively evaluated in relation to lipid profile. Therefore, identifying 
APOC4 genetic variants that modulate HDL-C level is a great public health importance. In this 
study we focused on the APOC4 gene and hypothesized that rare and common variants in this 
gene could affect plasma lipid levels. Integration of common variants common disease (CVCD) 
and rare variants common disease (RVCD) hypotheses has been conducted in a limited number 
of studies. The aim of this study was to identify both common and rare variants in APOC4 by 
sequencing individuals having extreme low and high HDL-C levels from U.S. non-Hispanic 
Whites (NHWs) and African Blacks, and to examine their effects on HDL-C and correlated lipid 
levels. In the sequencing analysis, a total of 65 variants were identified in NHWs and African 
Blacks. Of these 26 were present in NHWs and 51 in Blacks. Among NHWs, 31% of the low 
HDL-C group had rare or less common variants versus 10% of the high HDL-C group. On the 
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 v 
other hand, reverse trend was observed in the Black sample (46% of the low HDL-C group 
versus 54% of the high HDL-C). Screening of these observed rare and common variants in the 
complete NHWs and Blacks dataset would provide more information about their association with 
plasma HDL-C and correlated lipid traits. 
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1.0  IMPORTANCE AND SIGNIFICANCE 
1.1 CARDIOVASCULAR DISEASE 
1.1.1 Significance 
Coronary heart disease (CHD) continues to be a leading cause of premature mortality and 
morbidity in western countries. According to the American Heart Association Statistics in 2006, 
cardiovascular disease (CVD) accounted for 56% of all deaths in the US (American Heart 
Association, 2009; Tsompanidi et al., 2010). National Center of Health Statistics (NCHS) data in 
2006 estimated that 33% of premature deaths in US countries were attributed to CHD. Most 
strikingly, more than 81 million American adults live with various types of CVD and the 
estimated direct and indirect health care expenditures for 2006 were $165.4 billion (American 
Heart Association, 2009). 
In addition to being a leading cause of premature mortality, CHD is a major cause of 
morbidities. CHD is a medical condition in which coronary arteries that carry blood to the heart 
become hardened and narrowed or blocked the condition being called, atherosclerosis. 
Atherosclerosis is the major manifestation of CHD and is associated with different kinds of 
diseases such as, cardiac ischemia (lack of blood supply), necrosis, chest pain and myocardial 
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infarction. Taking all together, CHD is a major cause of co-morbidities and premature mortality 
in western countries and thus is a major public health problem. 
1.1.2 Cardiovascular Disease Risk Factors 
Several risk factors contribute to CHD, including cigarette smoking, abnormal blood lipid levels, 
hypertension, diabetes, abdominal obesity, lack of physical activity, low daily fruit and vegetable 
consumption, alcohol overconsumption and psychosocial index (American Heart Association, 
2009). 
Numerous epidemiological studies and long-term outcomes trials confirm the association 
between lipid level and CHD risk (Chilton, 2004). It is estimated that lowering cholesterol level 
reduces the CHD risk by 32% (Ravnskov, 1992). Clinical trials suggested that lowering fat 
dietary consumption reduces the CHD risk (Mozaffarian et al., 2010). By looking only at 
cholesterol level as a major CHD risk factor, each lipoprotein particle has a distinct role in 
determining atherosclerosis risk in which high density lipoprotein cholesterol (HDL-C) has a 
protective property against atherosclerosis, while low density lipoprotein (LDL-C) increases the 
atherosclerosis risk.  
1.2 LIPID AND CARDIOVASCULAR DISEASE 
Atherosclerosis is considered to be a major manifestation of CHD and there is a complicated 
mechanism underling the pathophysiological development of atherosclerosis. Atherosclerosis is 
mainly arisen due to lipid accumulation along the coronary artery walls, which results in 
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blocking the blood flow that leads to several co-morbidities. It has been well established that 
abnormal plasma lipid profile modulates the risk of CHD in which different lipoprotein particles 
play a complicated role in developing atherosclerosis (discussed below in the lipoprotein and 
lipid metabolism section).  
The opposite role of HDL-C and LDL-C in determining the CHD risk is well established 
in which high HDL-C is a protective factor, while increased LDL-C is a risk factor (Gordon et 
al., 1977). Interestingly 30-50% of patients with CHD have low HDL-C level (<40 mg/dl) 
(Sharrett et al., 2001). The inverse relationship between HDL-C level and CHD risk is well 
established. Each 1mg/dl increase in HDL-C decreases the risk of CHD by 2% in men and 3% in 
women (Gordon et al., 1989). On the other hand, 40% of CHD risk increases with each 38mg/dl 
increase in LDL-C level (Sharrett et al., 2001). In parallel, with each 10% reduction in LDL-C, 
the risk of CHD is decreased by 10% (Breil et al., 2009). 
CHD prevention approaches are aiming to modulate the cholesterol level either by 
lowering LDL-C or increasing HDL-C level or combining both approaches together (Ferns and 
Keti, 2008). Evidence from clinical trial study reveals the effectiveness of using the first 
approach (reducing LDL-C level) either by using LDL-C lowering drugs or changing the life 
style associates with reduction in the CHD risk (Sharrett et al., 2001). There is, however, 
controversy in using the second approach (increasing HDL-C) as CHD prevention measure. On 
one hand, majority of individuals with CHD have low HDL-C level and high TG level in spite of 
low LDL-C (Rubins et al., 1995), suggesting that HDL-C is independent predictor of CHD risk 
and increasing HDL-C might be more effective in CHD prevention. On the other hand, meta 
analysis of 108 controlled trials using lipid modulating medication shows non-significant 
association between high HDL-C level and reduction of CHD risk, suggesting that HDL-C is not 
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an independent protective agent (Briel et al., 2009).  Thus, whether lowering LDL-C or raising 
HDL-C level works independently is still a controversial issue. Thus, combining both approaches 
(lowering LDL-C and increasing HDL-C) would be the most effective preventive measure.  
1.3 LIPOPROTEIN AND LIPID METABOLISM 
1.3.1 Lipoprotein Particles 
Since lipid particles are water insoluble molecules (hydrophobic), they require special carriers to 
be transported in the circulation. Small fatty acids are transported through serum albumins while 
large lipids molecules such as cholesterol, phospholipids, and triglycerides need specialized 
carriers like lipoprotein particles. Lipoprotein particles are composed of two layers outer-layer 
(hydrophilic) and inner-layer (hydrophobic). The outer layer is composed of phospholipids, 
unesterified cholesterol and apolipoproteins, while the inner layer’s contents are cholesterol 
esters and triglycerides (Miles, 2003). The apolipoprotein component functions as modulators 
that facilitate internalizing the lipid through interaction with specific lipid receptors.  
Lipoproteins are classified into six different particles based on their densities and 
electrophoresis mobility (Mahely et al., 1984). The lipoprotein density is a factor of lipid to 
protein ratio with highest protein contents having the highest density and the slowest mobility. 
Lipoprotein particles are classified into six different particles: chylomicron, chylomicron 
remnants, very low density lipoprotein (VLDL), low density lipoprotein (LDL), intermediate 
density lipoprotein (IDL) and high density lipoprotein (HDL) (Corella and Ordovas, 2005; 
Mahely et al., 1984; King, 2010). 
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The key element of lipoprotein particles is apolipoprotein component that determines the 
lipoproteins specificity through interaction with specific lipid receptors. Apolipoproteins posses 
a unique feature that enables lipoproteins to bind to lipid molecules and this feature is called 
amphipathic. All apolipoproteins have ?- amphipathic helixes (both hydrophobic and 
hydrophilic ends) with a complex organization (Miles, 2003). The hydrophobic end had inward 
facing, while the hydrophilic end has an outward facing to interacts with the polar heads of 
phospholipids in order to facilitate internalizing the lipid particles (Miles, 2003).  
Apolipoproteins play essential roles in lipid transport and lipid metabolism by acting as 
ligands for lipid receptors or cofactor for some lipolytic enzymes such as, lipoprotein lipase 
(LPL), hepatic lipase (HL), cholesteryl ester transfer protein (CETP), or lecithin-cholesterol 
acyltransferase (LCAT) (Mahely et al., 1984). Apolipoproteins are key elements in regulating 
lipid level through transporting lipid to the liver, and maintaining vital function through 
distributing lipid to the cells and utilizing lipid in maintaining the integrity of cell membrane and 
synthesizing steroid hormones (Mahely et al., 1984). Additional function of apolipoproteins is to 
maintain the integrity of lipoprotein structure (Mahely et al., 1984). Apolipoproteins modulate 
their affinities during lipid metabolism and become exchangeable among different lipoprotein 
particles. There are different classes of apolipoproteins (apo) such as; apoAI, apoAII, apoAIV, 
apoB48, apoB100, apoCI, apoCII, apoCIII, apoCIV, apoE, apoD, apoF, apoJ, and apoM (Mahely 
et al., 1984). Since apolipoprotein CIV (apoCIV) belongs to apolipoproteins family, it is more 
likely involved in lipid metabolism and this is a candidate gene that might modulate HDL-C 
level.  
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1.3.2 Lipid Metabolism 
The lipid metabolism process is depicted in Figure 1. Lipid metabolism process begins with 
absorption of the dietary fatty acids in the intestine in Triglycerides (TG) form. The small fatty 
acids are transported through serum albumins to be taken directly either by metabolically active 
tissues such as, cardiac and skeletal muscle for energy or by adipose tissues for storage, while 
large lipid molecules require specialized lipoprotein particles. There are two major pathways of 
lipid metabolism: exogenous (dietary intake) and endogenous pathway (de novo lipid synthesis).  
The exogenous pathway begins once the dietary lipids are absorbed into the intestine and 
packaged by chylomicron particle to be transported into the circulation (Fitzgerald, 2010). 
Chylomicron particles are TG-rich with apoB48, apoAI, apoAII and apoAIV as major 
apolipoproteins (King, 2010). In the circulation, chylomicron undergoes several modifications, 
under lipoprotein lipase (LPL) action; its TG contents are hydrolyzed into glycerol and three free 
fatty acids. The free fatty acids are taken up either by muscle tissues for energy or adipose tissues 
for storage. Consequently, chylomicrons are transferred into smaller particles called chylomicron 
remnants (Corella and Ordovas, 2005; Mahely et al., 1984; King, 2010). Apolipoproteins are 
exchanged among lipoprotein particles with more than 90% of apolipoproteins remaining free in 
the circulation. After hydrolyzing the TG content of chylomicron, apoAI and apoAII are 
transferred to HDL particle resulting in chylomicron remnants with apoB48 as a major 
apolipoprotein. Chylomicron remnants acquire apoE from HDL particle, which plays a crucial 
role in TG clearance through hepatic uptake of chylomicron remnants by LDL receptors (LDL-
R) and LDL related protein 1 (LRP1) (Corella and Ordovas, 2005; Mahely et al., 1984; Miles, 
2003; King, 2010). After hepatic uptake of chylomicron remnants, the endogenous pathway 
begins. 
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In endogenous pathway, VLDL particles are synthesized in the liver by using cholesterol 
ester (CE) and phospholipids (PL) residues of chyomicron remnants and acquired apoB100, 
apoE and apoCs as apolipoproteins. Afterward in the circulation, VLDL undergoes similar 
pathway as chylomicron. VLDL is hydrolyzed by LPL and transferred into VLDL remnants 
(Corella and Ordovas, 2005; Mahely et al., 1984; Miles, 2003; King, 2010). Small portion of 
VLDL remnants is catabolized in the hepatic tissue through receptor-mediated mechanism 
involves remnants receptors, LDL-R and LRP1, while the majority of VLDL remnants 
transferred into IDL and eventually to LDL. As mentioned before apolipoproteins change their 
lipoproteins affinity and migrate to another lipoprotein during the lipid metabolism process 
(Miles, 2003). After LPL-mediated TG lipolysis of VLDL particles, VLDL loses apoCs and 
apoE that are acquired by HDL with retention of apoB100, the major apolipoprotein component 
of LDL. There are three major known fates for LDL-C: 1) hepatic clearance, 2) uptaken by 
extrahepatic tissues or 3) infiltrates into arterial walls and involved in atherosclerosis. Since up to 
70% of LDL-R are present in the liver, most LDL is uptaken by the liver and part of the 
remainder LDL is taken up by extrahepatic tissues for cellular membrane maintenance and 
steroid hormone synthesis (Grundy, 1983). Hepatic uptake of LDL cholesterol depends on the 
numbers of LDL-R expressed on the hepatic cells. The magnitude of intracellular cholesterol 
level down regulates the number of LDL-R (Grundy, 1983). Thus, there is negative feedback in 
which high intracellular cholesterol cuts down the number of LDL-R, which results in reducing 
the hepatic clearance of LDL-C and increasing the cholesterol level in the plasma. Eventually, 
presence of LDL-C at high level in the plasma results in penetration the arterial walls and 
accumulation of LDL-C on the intima, which initiates the atherosclerosis.  
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The atherogenic property of LDL-C is well documented and several randomized control 
trials and epidemiological studies confirm the direct relationship between LDL-C and CHD. 
High LDL-C is present in approximately 40-50% of patients with CHD (Griffin, 1999). The 
physical feature of LDL with a small molecular size enables LDL-C particle to penetrate the 
arterial walls (Grundy, 1983). Accumulation of LDL on the arterial walls is known as 
proatherogenic event. Under normal condition, no LDL-C is transferred to the arterial walls 
because majority of LDL-C is transported to the liver or into HDL-C. In individuals with high 
LDL-C, LDL-C accumulates on the arterial walls and once it is internalized, it gets oxidized 
(Adames et al., 2000). Oxidation process leads to the activation of endothelial region and triggers 
monocytes attraction. Monocytes modify into macrophages that engulf the oxidized LDL and 
transfer into foam cells. Then, inflammatory process takes place that results in severe damage 
and initiates the pathogenesis of atherosclerosis (Adames et al., 2000; Ross, 1999; Life Extension 
Foundation, 2010).  
Even though LDL is a major proatherogenic factor, other TG-rich lipoproteins (TGRL) 
have similar role in initiation atheroscerosis. Animal studies show association between high 
dietary intake of cholesterol and low hepatic uptake in rabbit and this association could be 
involved in atherosclerosis (Grundy, 1983). However, chylomicron remnants present at low 
concentration in humans due to maximum level of hepatic clearance, any defect in the hepatic 
uptake mechanism could result in accumulation of chylomicron remnants, which might lead to 
atherosclerosis (Grundy, 1983). 
Numerous in vitro studies showed the potential contribution of TGRL in 
proatherosclerosis mechanism. Several hypotheses presume TGRL involvement in 
atherosclerosis. Findings from cell culture study confirm the cytotoxic effects of TGRL on 
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endothelial cells (Spiedel et al., 1990). Furthermore, another in vitro study concluded that the end 
product of TGRL hydrolysis (free fatty acid) increases endothelial cells permeability and 
eventually increases LDL retention in the intima (Hennig et al., 1985). The relatively small 
molecular size of VLDL, VLDL remnants and LDL enable them to penetrate and being trapped 
into arterial intima (Hyson et al., 2003). Findings from various in vitro studies confirm the 
involvement of TGRL and its products in impairing the endothelial cells integrity and initiating 
atherosclerosis (Hyson et al., 2003). Another study concluded a direct correlation between 
triglyceride and LDL-C, which supports TGRL involvement in atherosclerosis (Krauss, 1991).  
Furthermore, TGRL promotes atherosclerosis not only by increasing LDL-C level but 
also by impairing the efficiency of RCT (reverse cholesterol transport) function of HDL particle. 
Patients with Tangier’s syndrome have low HDL-C and high VLDL due to mutation in ATP-
binding cassette sub-family A (ABCA1) gene (Corella and Ordovas, 2005). The possible 
mechanism underlying low HDL-C in Tangier’s disease is that High level of TG stimulates 
CETP to transfer TG from VLDL to LDL and to HDL that results in inefficient HDL particles. 
TG-rich HDL has an inefficient RCT function which accelerates the onset of atherosclerosis 
(Corella and Ordovas, 2005).   
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Figure 1 Lipoprotein Roles in Lipid Metabolism and Atherosclerosis (with permission from Rader and 
Daugherty, 2008) 
 
 
 
1.4 HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) 
HDL lipoprotein has the highest density with 45-55% apolipoproteins, 22-36% phospholipids, 
15-20% esterified cholesterol, 3-5% unesterified cholesterol and approximately 5% triglycerides. 
ApoAI and apoAII are the major HDL apolipoproteins with a crucial function in HDL 
metabolism. HDL also contains other apolipoproteins such as, apoCs and apoE (Tsompanidi et 
al., 2010).   
There are two main sources of HDL; de novo synthesis in the hepatic cells and intestine, 
or generated from other lipoprotins mainly LDL. HDL-C metabolism as illustrated by Fitzgerald 
(2010) in abcam website shows that HDL-C is generated primarily from other lipoproteins after 
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transferring the cholesterol and phospholipids into apoAI and forming pre B-HDL particle. ATP-
binding cassette (ABCA1) is the major catalyst of this process. Furthermore, LCAT enzyme 
plays important role in esterifying the cholesterol content of the nascent HDL and transferring 
the nascent HDL (disc-shaped) to a mature HDL (spherical-shaped) (Corella and Ordovas, 2005; 
Fitzgerald, 2010).  
The cholesterol content of HDL is taken up by the hepatic tissue either directly through   
scavenger receptors B1 (SR-B1) without internalizing HDL particle or indirectly through 
transferring cholesterol to other lipoprotein particles (VLDL and LDL) through LDL-receptor or 
LRP1-mediated hepatic uptake (King, 2010)). HDL-C is transferred to VLDL and LDL under 
action of HDL-related enzymes such as CETP (King, 2010). 
 
1.4.1 Antiatherogenic Feature of HDL-C 
Epidemiological studies confirm the inverse association between HDL-C and CHD. There are 
several hypotheses that explain the potential antiatherogenic property of HDL-C. Involvement of 
HDL in several mechanisms explains its atheroprotective function, including reverse cholesterol 
transport (RCT), antioxidant function and anti inflammatory function.  
One of the hypotheses is involvement of HDL in RCT. In RCT mechanism, HDL-C 
transports the cholesterol from extrahepatic tissue, including macrophages in the atherosclerotic 
lesion site to the liver for catabolism. Thus, RCT mechanism prevents accumulation of 
cholesterol in the extrahepatic tissue and arterial walls and in turn inhibits atherosclerosis 
initiation event (Tsompanidi et al., 2010; Assman et al., 1996). It is hypothesized that LCAT 
enzyme, that is activated by apoAI enhances the reverse cholesterol transport mechanism 
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through esterification of free cholestrol. Then, the esterfied cholesterol gets internalized into 
HDL lipid core and eventually catabolized in the liver, which results in alteration of the HDL 
particle configuration from disc-like to a spherical-shape particle. So, LCAT is involved in 
modifying a nascent HDL into mature HDL-C (Kris-Etherton and Etherton, 1982). 
In addition to the RCT mechanism, HDL has antioxidant property that provides direct or 
indirect protection of LDL from oxidation. This antioxidant property is mainly due to presence 
of apoAI and antioxidant enzymes. In vitro studies shows that apoAI inhibits LDL oxidation 
either by making LDL molecule resistant to lipoxygenase enzyme which involves in fatty acid 
oxidation, or by removing oxidation prone molecules from LDL and make it resistant to be 
oxidized. Additional molecule participates into antioxidant function is antioxidant enzymes such 
as, paraoxonase (PON) and acetyl-hydrolase platelet activation factor (PAFAH), which inhibit 
LDL oxidation (Corella and Ordovas, 2005; Tsompanidi et al., 2010). 
Additionally, HDL has antiinflammatory feature that provides protection from 
inflammation. Several in vitro studies show that HDL inhibits expression of pro inflammatory 
adhesion molecules (such as C-reactive protein and prostaglandins from monocytes) and 
???????????????????????????????????????????????????????????????????????????????in vitro studies 
concluded that involvement of HDL in stimulating endothelial nitric oxide synthase (eNOS), 
which functions as vascular relaxant (Tsompanidi et al., 2010). Furthermore, HDL has a major 
role in clearing away all the atherogenic agents. Phenotypic characteristic of Tangier’s syndrome 
with high TG and low HDL-C explains the major role of HDL in maintaining TGRL 
homeostasis. Taking all these findings together explain the antiatherogenic role of HDL (Corella 
and Ordovas, 2005).  
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Since elevated level of HDL and lower level of LDL predicts low risk of CHD, most 
therapeutic and prevention approaches targeting increasing HDL cholesterol level to minimize 
CHD risk.  
1.4.2 Genetics of HDL-Cholesterol 
The well-established inverse association between HDL-C and CHD risk provides compelling 
rational in identifying the genetic basis of HDL-C. Several family and twin studies have 
confirmed the genetic basis of HDL-C with an estimated heritability of 40-60% (Qasim and 
Rader, 2006; Lusis et al., 2004). To a lesser extent additional factors explain the remaining 
variation in HDL-C level, including age, gender, obesity, physical activity, diet, smoking, 
alcohol consumption and other metabolic disorder such as diabetes mellitus and liver diseases. 
The variation in HDL-C is a complex trait in which multifactorial genetic-environmental 
interaction takes place in modulating HDL-C level.  
Several linkage and association studies have been conducted over the last 30 years in 
order to determine the genetic basis of HDL-C level. Several monogenic susceptible loci that 
influence the high and low level of HDL-C have been identified. Familial 
hypoalphalipoproteinemia (FHA) is the most common monogenic disorder with extremely low 
level of HDL-C and apoAI. However, the monogenic susceptible loci, which have been 
identified, explain only 1% of HDL-C heritability (Miller and Zhan, 2004). Since HDL-C is a 
complex trait, there is a complicated mechanism influencing the variation of HDL-C level. There 
are two major approaches used to identify susceptible loci for complex diseases, including 
candidate gene studies and genome wide studies. 
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Candidate gene study is a hypothesis-based approach, which can be classified further into 
association studies and resequencing association studies (Weisglass-Volkov and Pajukanta, 
2010). Association studies compare the allele or genotype frequency in cases and control. Genes 
for association studies are chosen based on their location (under the linkage peak) or based on 
their biological role in the disease pathogenesis. Thus, we can classify candidate gene association 
studies into positional or biological candidate genes. The major difference between candidate 
genes association studies and resequencing association studies is the resolution (ability to detect 
common or rare variants). In candidate gene association studies, only common genetic variants 
with MAF ?????????????????????????? ???????????? ?????????????????????????????????? es (LD-
based studies). Only tag SNPs (the representative SNPs that are in LD with other proxies) that 
could give us information about their proxies are genotyped. In contrast to candidate gene 
association studies, the resequencing approach is LD-based free association studies in which the 
entire gene is sequenced to overcome the candidate gene association studies limitations in 
detecting rare variants with MAF<5%. Resequencing enables researchers to detect both common 
and rare variants. Although resequencing association studies have better resolution in identifying 
rare variants, it is an expensive and laborious approach (Weisglass-Volkov and Pajukanta, 2010). 
Many candidate gene association studies have been conducted over the past years 
(Weisglass-Volkov and Pajukanta, 2010). Numerous genes involved in lipid metabolism 
(includes: apolipoproteins, enzymes, receptors, lipid transfer protein, transporters and 
transcription factors) have been tested and yielded inconsistent results. The major reason behind 
inconsistency among various studies is insufficient sample size, which complicates identifying 
common SNPs with small to moderate effect sizes (Weisglass-Volkov and Pajukanta, 2010). 
Several susceptible loci have been identified using the candidate genes approach; CETP, LIPC, 
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LPL, LCAT, ABCA1, APOA1, APOC3, APOA5, APOE, SR-B1 and PON1 (Weisglass-Volkov 
and Pajukanta, 2010; Sviridov and Nestel, 2007; Klos and Kullo, 2007; Boes et al., 2009; Pollex 
and Hegele, 2007). Several candidate genes studies emphasized the genetic effect of some 
apolipoproteins such as APOA2, APOA4, APOE and APOB (Boes et al., 2009) but little attention 
has been paid to APOC4, which we have investigated in this study. 
The second category of genetic studies is genome wide study (GWS) that is also further 
classified into association or linkage studies. In GWS, common variants with MAF ??????????
the whole genome are genotyped under hypothesis-free settings. The major difference between 
genome wide association studies (GWAS) and genome wide linkage studies (GWLS) is the 
target population. GWAS are a population-based approach, while GWLS studies are family-
based approach (Weisglass-Volkov and Pajukanta, 2010).  
Linkage studies test the co-segregation of chromosomal regions among family members. 
Linkage studies are useful in localizing the causal variant of rare monogenic disorders but it is 
not applicable for complex diseases (Rust et al., 1998). Association studies are more powerful in 
detecting the genetic basis of complex diseases than linkage analysis in having better resolution 
and using fewer number of markers than linkage analysis (Weisglass-Volkov and Pajukanta, 
2010). Linkage with HDL-C has been reported on different chromosomes, including 9p (Arya et 
al., 2002), and chromosome 7 (Adeyemo et al., 2005) in Mexican American families. In Utah 
families, 11q23 was linked with HDL-C, while 8q and 15 were linked to HDL-C in San Antonio 
Hispanic families (Kort et al., 2000). Recent genome wide linkage study revealed significant 
linkage peak at chromosome 19p13 with a LOD score of 1.14 in population of Asian ancestry 
(Park, 2008). Meta analysis of Linkage studies on families with diverse ethnicity revealed a 
broad linkage peak on chromosome 19 (19p13-19q13.24) with different lipid traits, which 
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suggest that complex genetic interaction among different genes in this linkage region might have 
direct impact on modulating lipid profile (Malhotra et al., 2007). Most interestingly, 
APOE/C1/C4/C2 genes lie under this linkage region. 
GWAS opens a great opportunity for researchers to identify novel susceptible loci with 
no prior knowledge of their biological involvement in the etiology of complex disease 
pathogenesis. GWAS is a hypothesis free approach in which the common variants with MAF ??
5% in the genome are genotyped. Although GWAS have discovered numerous susceptible loci 
influence HDL-C level variation, they explain only 10% of HDL-C heritability (Kathiresan et al., 
2009). There are numerous assumptions explaining the GWAS missing heritability. One 
assumption is that the most common genetic variants have a small to moderate effect size that 
could not pass the GWAS significance level (p-value <5x10-8
To date, GWAS have discovered around ~ 40 loci influencing lipid level and about 16 
loci for HDL-C in European populations (Willer et al., 2008; Kathiresan et al., 2009; Aulchenko 
et al., 2009 and Sabatti et al., 2009). HDL-C susceptible loci are within or near these genes: 
ABCA1, angiopoietin-like-4 (ANGPTLA), APOA1/C3/A4/A5 genes cluster, APOB, CETP, free 
fatty acids desaturase (FADS (1/2/3)), N- acetylgalactosaminyltransferase 2 (GALNT2), hepatic 
nuclear factor (HNF4A), LCAT, LIPC, LIPG, LPL, MAP kinase activating death domain-folate 
hydrolase-nuclear oxysterol receptors (MADD-FOLHI-NRIH3), methylmalonic aciduria (MVK-
). Another assumption is that rare 
variants with a large effect size might account for a greater portion of HDL-C heritability and 
GWAS miss identifying rare variants because it is based on common variants common disease 
hypothesis (CVCD). Thus, integration of common variants common diseases (CVCD) and 
multiple rare variants common diseases (MRVCD) hypotheses would enable researchers to 
identify both common and rare variants.  
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MMAB), phospholipid transfer protein (PLTP) and tetratricopeptide repeat domain 39B 
(TTC39B) (Kathiresan et al., 2009).  
Susceptible loci influence HDL-C according to their role in HDL-C metabolism. 
According to Rader and Maugeals (2000), some genes with known role in accelerating reverse 
cholesterol transport (RCT) function (such as; ABCA1, LCAT, PLTP and LPL) result in 
increasing HDL-C, while other genes that participating in hepatic uptake of HDL-C and 
catabolism such as (SR-B1, HL and endothelial lipase) result in decreasing the HDL-C level.  
 
1.5 APOC4 GENE 
1.5.1 Gene Structure 
APOC4 was identified and characterized by Allan et al (1995) within the APOE/C1/C4/C2 gene 
cluster on chromosome 19q13.2. APOE/C1/C4/C2 is a 48 kb gene cluster in which APOC1 is 
located either 4.3 or 5.3 kb downstream from APOE gene with the same transcriptional 
orientation (Davison et al., 1986; Myklibost and Rogene, 1986; Lauer et al., 1988; Li et al., 
1988). There is one copy of APOC1 gene that is located 7.5 kb from APOC1 with no mRNA 
product in any tissue called, pseudo APOC1 gene. APOC4 is located 555 bp upstream from 
APOC2 with the same transcriptional orientation (Allan et al., 1995).  
APOC4 gene spans a 3.3 kb and composed of three exons and two introns (Figure 2). 
APOC4 sequence encodes 127 amino acids with 25 residues in the signal peptides (Allan et al., 
1995). The first exon encodes most of the signal peptides while the second one encodes the C-
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terminal region. Each of the second and third exon has amphipathic helical structure, lipid-
binding domain (Zhang et al., 1996). Exon 1 encodes for amino acid 1-25, exon 2 encodes for 
amino acid 26-73 and exon 3 encodes for the remaining amino acid (Kotite et al., 2003).  
 
 
 
Figure 2 APOC4 Gene Structure with Three Exons and Two Introns (adopted from SeattleSNPs database) 
 
  
 
 
The expression of all four genes in this cluster, APOE/C1/C4/C2, is regulated by two 
(600 bp) hepatic control elements (HCE-I and HCE-II) (Allan et al., 1995; Simonet et al., 1993). 
These two hepatic control elements work independently; presence of one HCE is enough for 
sufficient expression of each gene in this cluster (Shachter et al., 1993; Simonet et al., 1993; 
Allan et al., 1995; Allan et al., 1997). 
APOC4 is expressed only in the liver with undetectable level in the plasma. RNase 
protection analysis, confirmed the lower expression of APOC4 in the liver with approximately 
100-fold lower than the expression of APOC2 gene (Allan et al., 1995). In comparison with the 
mice Apoc4 gene sequence, the human APOC4 promoter lacks the typical TATA box motifs. So, 
presence of transcription factor binding sites (Sp1) is necessary for gene expression. At least 
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three Sp1 are required for binding with the transcription factor to initiate transcription process 
(Allan et al., 1995). Moreover, human APOC4 gene contains five Sp1 like-motif sequences with 
GGAGGG instead of GGCGGG (with C>A substitution). It has been found that (C>A) 
substitution in Sp1 like motif associates with three-fold reduction in the binding affinity of Sp1 
motif to the transcription factor, which partially explains the lower expression rate of APOC4 
mRNA in the liver (Allan et al., 1995).  
Zhang et al. (1996) reported the lower expression rate of APOC4 in human liver 
compared to other species such as rabbits. It has been found that the Rabbit Apoc4 gene is similar 
to human APOC4 gene in lacking a typical TATA box in the 5’flanking region with one 
exception (Kotite et al., 2003). Rabbit Apoc4 gene contains a purine-rich sequence 
GGGACAG(G/A) repeated nine times in tandem within the 5’UTR with two  additional repeats 
in the 5’ flanking region, whereas human and mouse APOC4 gene contains only one copy of this 
purine-rich sequence (Kotite et al., 2003). In human APOC4, the purine-rich sequence is located 
at position 527-533bp in the 5’flanking region according to reference sequence of APOC4 in 
SeattleSNPs database. Since purine-rich sequence is involved in transcription of numerous 
genes, the higher number of purine-rich sequence repeats in rabbit explains the higher expression 
level of Apoc4 gene in rabbit than in human (Kotite et al., 2003).  
There are several hypotheses explaining the low expression rate of APOC4 mRNA in 
human liver compared to the other apolipoproteins. Lacking the TATA box motif, weak Sp1 
motifs and presence of only one copy of the purine-rich sequence, as described above, explain 
part of the lower expression rate of APOC4 gene in human liver compared to the rabbit. 
SDS-PAGE analysis revealed presence of four different isoforms of APOC4 with 12.5-19 
kDa. This high molecular mass is a result of complex N-linked oligosccharides with variable 
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sialylations (Allan et al., 1996). ApoCIV protein structure resembles other apolipoproteins 
structure in having two amphipathic a-helical structures (lipid binding domain). Segrest et al 
(1994), localized the lipid binding domain in the exchangeable apoplipoproteins by using 
LOCATE program. They found that apolipoproteins contain a special amphipathic feature that 
facilitates lipid-binding function. Class A1 helical structure is located within the second exon 
between residues (47-74) in which the positively charged proteins arranged as polar-nonpolar 
interface and negatively charged proteins present at the center of polar face. The second helical 
structure is class Y, which is located within the thirds exon between (95-116) residues. In the Y 
class helical domain, the positively charged proteins present at the center of polar interface 
(Segrest et al., 1994; Allan et al., 1995). ApoCIV unique structure suggests its involvement in 
lipid metabolism. 
1.5.2 Biological Function of ApoCIV 
In vitro studies have shown several regulatory effects of apoCs on different enzymes and 
receptors involved in lipid metabolism (Jong et al., 1999). Conservation of APOC4 genomic and 
protein structure among different species implies the significant role of apoCIV in human (Allan 
et al., 1995). ApoCIV protein structure with two amphipathic helical domains suggests its 
involvement in lipid metabolism (Allan at al., 1995). Moreover, Kim et al. (2008) reported that 
overexpression of APOC4 in patients with hepatitis C virus infection (HCV) and those patients 
manifest liver steatosis, suggesting that overexpression of APOC4 interferes with TG metabolism 
which results in TG accumulation and liver steatosis (Kim et al., 2008).  
ApoCs are present on VLDL and HDL lipoproteins. In postprandial condition, apoCs are 
transfered from HDL to chylomicron and VLDL (Jong et al., 1999). In normotriglyceridemic 
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condition, more than 80% of apoCIV is present on VLDL (representing 0.7% of apo VLDL) and 
most of the remainder is on HDL, while apoCI and apoCII distribute equally on both HDL and 
VLDL (Kashyap et al., 1977; Schonfeld et al., 1979). Overexpression of APOC4 in transgenic 
mice causes hypertrigylceridemia suggests a direct association between apoCIV and TG 
metabolism (Allan et al., 1996). This phenotype resembles the resulting phenotype of 
overexpression other apoCs (apoC1, C2 and C3) (Aalto-Setala et al., 1992; deSilva et al., 1994; 
Shachter et al., 1994; Simonet et al., 1991). The similar hypertrigylceridemic phenotype of 
expression all apoCs suggests that all human apoCs have a common underlying mechanism in 
trigylceride metabolism (Allan et al., 1996). There are two assumptions behind accumulation of 
TG-rich lipoprotein (VLDL) in APOC4 transgenic mice: 1) impairing hepatic uptake of VLDL 
through interfering with apoE mediated cellular uptake, and 2) impairing the TG lipolysis 
mechanism through interfering with LPL or HL activity (Allan et al., 1996). 
Numerous evidences from several studies support the first assumption behind VLDL 
accumulation, impairing the hepatic uptake of VLDL. In transgenic mice, overexpression of 
APOC2 and APOC3 is associated with elevated TG level with minimum changes on total 
cholesterol level due to interference with hepatic uptake of TG-rich lipoprotein (VLDL) (Aalto-
Setala et al., 1992; de Silva et al., 1994; Shachter et al., 1994). Furthermore, in vitro studies have 
reported that APOC1 and APOC2 overexpression impairs VLDL binding to LRP1 receptors 
through displacing apoE (Swaney and Weisgraber, 1994; Weisgraber et al., 1990). Similar 
findings from other studies   confirm   that expression of apoCs interferes with apoE-mediated 
hepatic uptake of VLDL and LDL through impairing the interaction between apoE and LDL 
receptor (Sehayek and Eisenberg, 1991). In parallel, the findings of hypertrigylceridemic 
phenotype in APOC4 transgenic mice without change in LPL and hepatic lipase activity, 
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supports the first assumption behind VLDL accumulation (Allan et al., 1996). Most probably, the 
potential underlying mechanism behind VLDL accumulation is related to impairing apoE-
mediated hepatic uptake of VLDL through interaction with LDL-R or LRP1 receptors without 
disturbing triglyceride lipolysis mechanism (Allan et al., 1996).     
Conservation of APOC4 coding region sequences among different species suggests the 
significant function of apoCIV. It is assumed that expression of APOC4 is associated with the 
developmental stage and disease status, suggesting that the expression of APOC4 is low under 
normal condition and could be increased under certain condition such as acute illness (Allan et 
al., 1996). Overexpression of APOC4 in patients with HCV infection supports the possibility of 
increasing APOC4 expression under acute illness (Kim et al., 2008). Additional evidence from in 
vitro study suggests the potential role of apoCIV in lipid metabolism and atherosclerosis. 
Expression of ApoE/C1/C4/C2 genes cluster in lipid-loaded macrophages, suggests their 
potential antiatherogenic role in cholesterol efflux in a manner similar to the RCT mechanism 
(Mak et al., 2002).  
 
 
1.5.3 Genetic of APOC4 
According to Chip bioinformatics database, about 180 SNPs (single nucleotide polymorphisms) 
have been identified in the APOC4 gene. Although several studies have been conducted to 
identify genetic variants in the entire APOE/C1/C4/C2 genes cluster, a little attention has been 
paid to examine the extent of genetic variants in the APOC4 gene individually.  
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Genome wide linkage scans in the Strong Heart Family Study (SHFS) identified strong 
linkage signal with LDL-C on chromosome 19q13.41 with LOD score of 4.3 (North et al., 2006). 
Several candidate genes are present under this linkage region, including APOE/C1/C4/C2 gene 
cluster. Most interestingly, no significant association was found between APOE genetic variants 
and LDL-C in SHFS, suggesting that other genetic variants in nearby genes could be responsible 
for the linkage signal (North et al., 2006). In parallel, meta-analysis of linkage studies performed 
on families with type II diabetes mellitus revealed strong linkage with multiple lipid traits at this 
locus on ch19q13.13-13.43 in populations with diverse ethnic history, including total cholesterol 
and LDL-C (Malhorta et al., 2007). In the same study they found broad linkage peak on 
chromosome19 (19p12-q13.13), which could explain the complexity of the genetic of lipid in 
which multiple genes interact with each other and modulate lipoproteins concentration (Malhorta 
et al., 2007). 
Moreover, GWAS in 2008 confirmed association signal of (rs4420638, APOC1) at 
APOE/C1/C4/C2 genes cluster with LDL-C (p=1x10-60
To our knowledge, there is only one previous study aimed to detect genetic variants in the 
APOC4 gene. Kamboh et al. (2000) identified five SNPs in the coding regions and their exon-
intron boundaries of the APOC4. Two SNPs were at nt.968 and nt.979 in non-coding part of the 
) (Kathiresan et al., 2008). Several 
hypotheses explain the difficulties of identifying functional alleles in GWAS studies.  GWAS is 
unable to detect rare variants with modest or high effect size, and common variants with small to 
modest effect size. It is possible that there are multiple rare variants in APOC4 that are 
associated with lipid profile but they were not identified in GWAS. For this reason, we are 
integrating CVCD and MRVCD hypotheses to detect both common and rare variants in the 
APOC4 gene.  
  24 
first exon, two SNPs were at codon 36 and 52 in the second exon, and one was at codon 96 in 
exon 3. Significant association was found between Pro36Leu and Leu96Arg and elevated TG 
level in NHW women (p= 0.03 and 0.08, respectively). Another association was found between 
SNP at nt.979 and HDL-C level in NHW men and Lp (a) levels in NHW women with p= 0.05. 
These APOC4 genetic variants explained only 2% of the TG variation (Kamboh et al., 2000). 
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1.6 SPECIFIC AIMS 
The objective of this study was to examine the role of complete genetic variants in the APOC4 
gene in relation to plasma lipid profile in two racial groups comprising non-Hispanic whites 
(NHWs) from the US and African Blacks from Nigeria. Since APOC4 is a candidate gene, we 
tested both CVCD and MRVCD hypotheses in order to identify both common and rare variants. 
The objectives of this study were fulfilled by carrying out the following aims: 
Aim 1: 
Resequence the entire APOC4 gene in individuals with extreme HDL-C levels falling in the 
upper fifth percentile (47 whites, 48 Blacks) and lower fifth percentile (48 Whites, 47 Blacks) to 
detect both rare (MAF < 5%) and common (MAF ??????????????? 
Aim 2: 
Examine the distribution of common and rare variants identified in Aim 1 between the high and 
low HDL-C groups. 
Aim 3: 
Genotype APOC4 common tag SNPs in the entire samples of NHW (n=623) and Black (n=788), 
and to examine their association with plasma lipid profile. 
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2.0  SUBJECTS AND METHODS 
2.1 SUBJECTS 
2.1.1 Study Population 
We used two well-characterized epidemiological samples, including non-Hispanic whites 
(NHWs) (n=623) and African Blacks (n=788).  NHW samples were collected as part of the San 
Luis valley Diabetes Study (SLVDS). SLVDS was established as geographical based case-
control study of non-insulin dependant diabetes mellitus and cardiovascular disease in Alamosa 
and Conejos counties of south Colorado (Hamman et al., 1989). The demographic and health 
data and other confounding factors such as dietary intake, smoking, alcohol consumption and 
physical activity were collected from all participants. The basic characteristics of this study are 
described in Rewers et al. (1993) and Hamman et al. (1989). Samples of African Black were 
recruited in Benin City, Nigeria as part of study on CHD risk factors in Blacks. Participants’ 
demographic and health information were collected and more information can be found in 
Bunker et al. (1995, 1996). The demographic characteristics of both populations are summarized 
in Table 1. 
Esterase-oxidase method was used to measure total cholesterol level. Total HDL-C and 
LDL-C level were determined enzymatically after dextran sulfate magnesium precipitation 
  27 
(Harris et al., 1998; Richmond, 1973), and trigylceride level was determined enzymatically by 
using Stavropoulous and Crouch procedure (Stavropoulous and Crouch, 1974). The DNA used 
for sequencing and TaqMan genotyping was extracted from clot sample in Blacks and from 
Buffy coat in NHWs using standard DNA extraction procedures. 
 
 
             Table 1 Demographic Characteristic of Study Populations 
Variable 
NHWs (n=623) 
Men                     Women 
African Blacks (n=788) 
Men                     Women 
Sample size (n) 295 328 495 293 
Age (Yrs) 52.9 ± 0.6 52.4 ± 0.6 42.5 ± 0.4 38.7 ± 0.4 
BMI (kg/m2 26.2 ± 0.2 ) 24.8 ± 0.2 22.0 ± 0.2 24.3 ± 0.3 
LDL-C (mg/dl) 139.8 ± 2.0 134.7 ± 2.0 104.7 ± 0.1 117.3 ± 0.1 
HDL-C (mg/dl) 43.9 ± 0.6 56.3 ± 0.7 45.9 ± 0.6 50.6 ± 0.7 
Triglycerides (mg/dl) 147.6 ± 4.1 128.2 ± 2.9 77.8 ± 1.7 62.8 ± 1.4 
Total cholesterol 
(mg/dl) 
213.7 ± 2.2 217.7 ± 2.1 167.7 ± 1.6 181.3 ± 2.2 
 
 
2.1.2 Resequencing Samples 
Ninety-five NHWs (47 individuals having high HDL-C and 48 having low HDL-C) and ninety-
five African Blacks (48 having high HDL-C and 47 having low HDL-C) were selected for 
APOC4 gene resequencing to detect both rare and common variants. The characteristics of 
subjects selected for resequencing are summarized in Table 2. 
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              Table 2 Characteristics of APOC4 Resequencing Samples 
 
NHWs (n=95) African Blacks (n=95) 
(high HDL-C) 
(n=47) 
(low HDL-C) 
(n=48) P-value 
(high HDL-C) 
(n=48) 
(low HDL-C) 
(n=47) P-value 
Sex (M/F) 24/23 24/24 0.92 24/24 23/24 0.92 
Age (Yrs) 
 55.45 ± 9.8 53.03 ± 10.54 0.25 41.26 ± 8.72 40.87 ± 7.16 0.8 
BMI (kg/m 23.17 ± 3.17 2) 27.35 ± 3.90 <0.001 22.06 ± 4.71 23.91 ± 5.51 0.08 
TOTAL-C 
(mg/dl) 227.34 ± 51.76 208.81 ± 44.65 0.06 201 ± 39.68 141.68 ±31.03 <0.001 
LDL-C (mg/dl) 126.84 ± 46.95 136.95 ± 41.28 0.28 112.55 ± 39.75 95.04 ± 28.28 0.02 
TG (mg/dl) 114.09 ± 60.88 240.21±153.22 <0.001 61.98 ± 19.85 95.79 ± 73.21 0.003 
HDL-C (mg/dl) 77.68 ± 13.32 31.81 ± 4.37 <0.001 76.05 ± 7.53 25.51 ± 5.66 <0.001 
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2.2 METHODS AND MATERIAL 
 
2.2.1 PCR Amplification and Sequencing 
Publicly available information at SeattleSNPs database (http://pga.mbt.washington.edu/) was 
used to order M13 tagged primers, which generated seven overlapping fragments. These primary 
Seattle primers cover genomic region of 4,510 bp that includes 956 bp in the 5’flanking region, 
all 3 exons (614 bp), 2 introns (2,644 bp), and only 297 bp in 3’flanking region. To extend the 
amplified sequences on the 3’flanking region, we adopted additional sequences (576 bp) located 
at (4511-5086) bp from CHIP database to amplify 873 bp in the 3’flanking region and we 
designed PCR primer to amplify this region. For some fragments there are multiple primers sets 
(fragment 1, 4, 7), Table 3 lists the primer sets used in this study for PCR amplification. Because 
of having difficulties in amplifying fragment 4, we designed PCR primers to fill out the gap 
between the third and fourth fragment. We had sequence gap within fragment 3 in both samples 
(NHWs and African Blacks) and in fragment 7 in the African Blacks samples, and for this reason 
we designed internal sequencing primers to fill these gaps. Primer3 software version 0.4 
(http://frodo.wi.mit.edu/primer3/) was used to design PCR and sequencing primers. The primers’ 
sequences are summarized on Table 3. 
  
Table 3 Polymerase Chain Reaction (PCR) Primers 
Frag
ment	  
Fragme
nt	  size	   Forward	  Primer’s	  Sequence	   Reverse	  PCR	  Primer’s	  Sequence	   Internal	  Sequencing	  Primers	  *	  
1	   (711)bp	   5’-­‐tgtaaaacgacggccagtGAGACGGAGTCTTGCTCTTTCGC-­‐3’	  	   3’-­‐caggaaacagctatgaccTCAGTTTCCTCCTCCATAAAGTG-­‐5’	  	   	  
2	   (807)bp	   5’-­‐tgtaaaacgacggccagtATTACAGGCACGCATCACTACTT-­‐3’	  	  
3’-­‐caggaaacagctatgaccCACACAGATGATCCCAGTTTGTA-­‐5’	  
	   	  
3	   (800)bp	   5’-­‐tgtaaaacgacggccagtGTGAGAAGAAGTGGGTGGAGG-­‐3’	  	  
3’-­‐caggaaacagctatgaccGTCAGGATATGGAGACCATCCTG-­‐5’	  
	  
5’-­‐GCATGTCTGTGTGCATATGTGT-­‐3’	  
3’-­‐GTGGCGTGTGTCTGTAGTCC-­‐5’	  
4*	   (320)bp	   5’-­‐CCAGGATGGTCTCCATATCC-­‐3’	  	  
3’-­‐GTGCCTGGCCCTGTATTAAA-­‐5’	  
	   	  
5	   (848)bp	   5’-­‐tgtaaacgacggccagtATTCTAGATCAGCATTATCCAGTA-­‐3’	  	  
3’-­‐caggaaacagctatgaccTCTTCACCTTGTGTCAGTAGTCC-­‐5’	  
	   	  
6	   (1010)bp	   5’-­‐tgtaaaacgacggccagtGTCCACAGAGGTAGCTCAGACAG-­‐3’	  	  
3’-­‐caggaaacagctatgaccGCTCCTCTCTGTGACCTAGGAGT-­‐5’	  
	   	  
7	   (986)bp	   5’-­‐tgtaaaacgacggccagtAAAGCTAAAGATGAGTCGCTGG-­‐3’	  	  
3’-­‐caggaaacagctatgaccGGAGTCAGAGCTTGTAGGAGACA-­‐5’	  
	  
5’-­‐CAGAGAACACCTGGGGAGAG-­‐3’	  
3’-­‐AAGAGATCTCGCTGTGTTGC-­‐5’	  
8*	   (739)bp	   5’-­‐CTTCAAGGCGTGTCAGTTTC-­‐3’	  	  
3’-­‐ATTTGTGGAGTGTGGTGGTG-­‐5’	  
	   	  
Lowercase represent M13-tag primers, while uppercase represent primers sequence, * represents the primers we designed. 
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These amplicons generated eight overlapping fragments that covered a total genomic 
region of 5,086 bp, including 956 bp in the 5’flanking region, 614 bp of exons, 2,644 bp of 
introns, and 876 bp in the 3’ flanking region. The entire gene was sequenced from both 
directions. There were two small gaps 33 bp between (1842-1875 bp) and 16 bp between (2147-
2163). The polymerase chain reaction (PCR) reaction and cycling condition are summarized in 
Table 4. As part of optimization process, some modifications have been made either by 
increasing MgCl2
 
, changing the annealing temperature, or using DMSO for CG-rich regions 
during the PCR reaction. 
 
          Table 4 PCR Reaction and Cycling Condition 
PCR Reaction Conditions 
(Reaction volume 25 µL) 
PCR Cycle 
Genomic DNA (1ng/dl)                   3.0 µL 1. 95????????? ??????? 
2. 95?????????????? 
3. 58-60????????????? 
4. 72????????? ??? 
Repeats 2-4 for 40 cycles 
5. 72?????????? ??? 
6. Cool down to 4?? 
M
as
te
r M
ix
 
(2
2µ
L)
 
   
 
d.H2O                                                   11.75-13.25 µL 
10x BufferGold 2.5 µL 
MgCl2 1.5-3.0 µL (25 mM) 
dNTPs (1.25 mM) 3.8 µL 
Forward Primer (20 mM)  0.4 µL 
Reverse Primer  
(20mM) 
0.4 µL 
Tag Polymerase enzyme 
Enzyme (5U/µL)  
0.15 µL 
 
 
After PCR, gel electrophoresis was performed to confirm DNA amplification prior to 
DNA sequencing. Invitrogen TM E-Gel® 96 2% with SYBR® Safe precaste gels (Invitrogen 
corporation, Carlsbad, CA) was used for large scale PCR, while regular 2% agarose gel was used 
for small scale PCR for samples that failed in the initial DNA amplification. The amplified 
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samples were sent to a commercial lab for automated fluorescence-based cycle sequencing and 
capillary electrophoresis on ABI 3730x1DNA Analyzers (Genomic Services of Beckman Coulter 
Genomics, Denver, MA). Variant Reporter version 1.0 (Applied Biosystem, Foster City, CA) 
and Sequencher version 4.8 (Gene Codes Corporation, Ann Arbor, MI), were used to analyze 
sequencing data. 
 
 
2.2.2 TaqMan Genotyping of APOC4 Common Variants 
A total of seven TaqMan premade SNP genotyping assays were ordered to genotype 4 tag SNPs 
in NHWs and 7 tag SNPs in Blacks. Genotyping data of Utah residents with Northern and 
Western European ancestry from the CEPH collection (CEU) and Yoruban in Ibadan, Nigeria 
(YRI) populations were obtained from publicly available HapMap database by using HapMap 
release #27 (www.hapmap.org) that covered the same APOC4 region used in resequencing. Tag 
SNPs for both populations were selected by running Tagger option in Haploview program 
(Broad institute of MIT and Harvard, 2010) at r2 
 
cutoff 0.7 and MAF cutoff 0.049.  There were 2 
tag SNPs bins in CEU versus 7 tag SNPs bins in YRI. TaqMan assays for 6 out of 7 tag SNPs 
bins were available and 3 out of these 7 TaqMan assays were corresponding to 1 tag SNP bin in 
CEU, and the remaining tag SNP bin in CEU (rs5158) was genotyped also in Blacks. Thus, we 
genotyped 4 tag SNPs in NHWs and 7 tag SNPs in blacks. Information related to tag SNPs and 
TaqMan SNP genotyping assays is summarized in Table 5 and Table 6, respectively. 
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Table 5 Tag SNPs and Captured Alleles in CEU and YRI 
CEU YRI 
Bin no. Allele captured Genotyped SNP Bin no. Allele captured Genotyped SNP 
1 rs5167 (3927) 
rs2288911 (4746) 
rs5157 (2623) 
rs2288912 (4661) 
rs5167 
rs1132899 (3498) 
rs5157 
rs1132899 
1 rs12709884 (4154) 
rs5159 (2971) 
rs12721104 
rs12721104 (3380) 
2 rs5158 rs5158 (2640) 2 rs2288911 (4746) 
rs2288912 (4661) 
------ 
   3 rs5167 rs5167 (3927) 
   4 rs5155 rs5155 (2559) 
   5 rs5157 rs5157 (2623) 
   6 rs10425530 rs10425530 (4157) 
   7 rs1132899 rs1132899 (3498) 
Bolded SNPs represent the genotyped SNPs by TaqMan.  
 
 
 
 
Table 6 TaqMan SNPs Genotyping Assays 
 
 
 
 
 
 
 
 
 
SNP reference ID Position on NCBI Assay type Functional 
Location 
Assay ID Population 
rs1132899 45448036 Premed missense  C__1841831_10 NHWs & Blacks 
rs5158 45447178 Premade intron C__11466146_10 NHWs & Blacks 
rs5157 45447161 Premade intron C__1841830_10 NHWs & Blacks 
rs5155 45447097 Premade intron C__26681856_10 Blacks 
rs10425530 45448695 Premade 3’UTR C__29686817_10 Blacks 
rs12721104 45447918 Premade intron C__33605659_10 Blacks 
rs5167 45448465 Premade missense C__1341833_20 NHWs & Blacks 
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TaqMan genotyping involves DNA amplification and end-point fluorescence reading 
using the ABI Prism 7900HT instrument. The TaqMan genotyping Master Mix and Assay were 
added to dried whole genome amplified DNA in 384-well plate. For TaqMan genotyping we 
followed ABI manufactures protocol (Applied Biosystem, 2007) with some modifications on the 
DNA concentration and the number of cycle that are illustrated on Table 7.  
 
 
            Table 7 TaqMan SNPs Genotyping Condition 
TaqMan Reaction total volume (5?L) PCR condition 
d.H2O 2.43 ?L 1. 95????????? ??? 
2. 95??????45 sec. 
3. 60???????? ??? 
    -repeat 2-3 49x 
Master Mix 2.5 ?L 
Assay 0.06 ?L 
 
 
2.3 STATISTICAL ANALYSIS 
Allele and genotype frequencies were determined by using direct counting. Concordance of the 
genotype distribution to Hardy-Weinberg Equilibrium (HWE) was tested using chi-squared (X2) 
test for each variant. Haploview software was used to analyze the variant allele frequencies, their 
distributions among low and high HDL-C groups, and their LD patterns. For the resequencing 
samples, X2 test was used to compare the allele frequencies between low and high HDL-C 
groups. For those SNPs that were genotyped in the entire samples, linear regression was 
performed to test the effects of genotypes on the means of four lipid traits (total cholesterol, 
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HDL-C, LDL-C, and TG). To minimize the effect of non-normality, natural log transformation 
was used to transform HDL-C and TG values in NHWs. In Blacks, log transformation was used 
to transform total cholesterol and TG, and the square root transformation used to transform 
HDL-C and LDL-C. The significant covariates were identified using stepwise regression in both 
directions. In NHWs, covariates included in the final model were gender, age, BMI (weight 
[kg]/height [m]2), and smoking. Among Blacks: gender, age, waist, Jobmin (minutes walking or 
bicycling to work each day (min)), and Staff (staff level (junior/senior)) covariates were included 
in the analysis. The additive and dominant models were used for data analysis. The R statistical 
software package (version 2.3.1, http://www.r- project.org) and Statistical Analysis Software 
(SAS) were used to perform all computations. A p-value of less than 0.05 under one of these 
models was considered as suggestive evidence of association. 
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3.0  RESULTS 
3.1 APOC4 RESEQUENCING 
Resequencing of the APOC4 gene in 190 NHW chromosomes (94 in high HDL-C group and 96 
in low HDL-C group) and 190 African Black chromosomes (96 in high HDL-C group and 94 in 
low HDL-C group) revealed a total of 65 variants, including one dinucleotide microsatellite. 
Table 8 summarizes APOC4 variants identified in this study in NHWs and Blacks. Of these 
observed 65 variants, one was a dinucleotide microsatellite, 4 were insertions or deletions 
(indels), and the remaining 60 variants were single nucleotide substitutions (SNPs). Of the 65 
variants identified, 15 were located in the 5’flanking region, 1 was in the 5’UTR, 29 were in 
introns, 2 were in splice sites, 7 were in exons, 2 were in the 3’ UTR and 9 were in the 3’ 
flanking region. Twenty-six variants were present in NHWs, 51 were observed in African Blacks 
and 13 were present in both (Figure 3). Five of the seven exonic variants were non-synonymous 
resulting in amino acid changes, including two new (3969A>C [Lys110Tyr] and 4012G>A 
[Lys124Arg]) observed in Blacks only at low frequency (0.011 and 0.005, respectively). While 
26 of the observed variants have previously been reported in databases (SeattleSNPs or CHIP), 
we observed 39 new variants in this study, including the dinucleotide microsatellite repeats at 
position 4929-4959 bp in both populations. For all samples in both populations there was GC 
instead of CG at position 1722-1723 bp, which is different from the reference sequence.  
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Table 8 APOC4 Variants Identified in NHWs and Blacks 
APOC4  
variants  
Position  
(bp)  
Base  Change   Ref  SNP  ID   Location   Amino  acid  change   NHWs  
  
MAF%                    Call  rate%  
Blacks  
  
MAF  %          Call  rate%  
65   C>T        5’  flanking  region                  0.007   77.9  
92_94   del3   rs12721101   5’  flanking  region        0.259   87.4   0.262   86.3  
108   G>A        5’  flanking  region        0.259   87.4   0.262   86.3  
116   A>G        5’flanking  region        0.007   78.9            
150_151   ins114        5’  flanking  region        0.256   88.4   0.283   94.7  
204   A>G   rs4803773   5’  flanking  region        0.235   52.6   0.233   94.7  
233   C>T        5’  flanking  region                  0.006   93.7  
245   G>T        5’  flanking  region                  0.006   94.7  
368   A>G        5’  flanking  region                  0.011   93.7  
438   G>A        5’  flanking  region                  0.006   94.7  
489   C>T        5’  flanking  region                  0.017   93.7  
636   C>T        5’  flanking  region        0.005   97.9            
637   G>T   rs73558107   5’  flanking  region                  0.043   98.9  
757   C>A   rs12721105   5’  flanking  region                  0.054   97.9  
870   G>A        5’flanking  region        0.005   97.9            
968   A>G        5’  UTR        0.038   97.9            
1088   T>G        splice  site                  0.006   91.6  
1130   T>C        intron  1                  0.005   97.9  
1150   A>G        intron  1        0.005   100            
1192   G>A        intron  1                  0.006   91.6  
1229   G>C        intron  1        0.011   100            
1325_1327   del3        intron  1        0.147   89.5   0.047   89.5  
1430_1431   Ins1        intron  1                  0.033   94.7  
1702   G>A   rs12721102   intron  1                  0.006   91.6  
1719   C>A        intron  1                  0.006   91.6  
1733   C>T   rs1271111   intron  1        0.263   82.1   0.244   90.5  
1823   C>G        intron  1        0.187   78.9   0.203   77.9  
2063   C>G        intron  1        0.005   98.9            
2099   G>T        intron  1                  0.011   98.9  
2467   C>T        intron  1                  0.017   92.6  
2557   C>A        intron  1        0.006   91.6            
2559   C>T   rs5155   intron  1                  0.088   95.8  
2607   G>A   rs5156   intron  1                  0.016   96.8  
2623   C>T   rs5157   intron  1        0.477   90.5   0.163   96.8  
2640   C>T   rs5158   intron  1        0.153   92.6   0.033   95.8  
2641   G>A        intron  1                  0.005   97.9  
2678   G>C        intron  1                  0.005   96.8  
  38 
Table 8 (Continued) 2683	   G>A	   rs12721109	   intron	  1	   	  	   0.011	   92.6	   	  	   	  	  2767	   G>T	   rs12721107	   intron	  1	   	  	   	  	   	  	   0.017	   93.7	  2971	   A>G	   rs5159	   intron	  1	   	  	   	  	   	  	   0.15	   94.7	  3213	   T>C	   rs28616151	   intron	  1	   	  	   	  	   	  	   0.056	   93.7	  3348	   G>A	   	  	   intron	  1	   	  	   	  	   	  	   0.006	   86.3	  3363	   G>A	   	  	   intron	  1	   	  	   	  	   	  	   0.043	   85.3	  3380	   G>A	   rs12721104	   intron	  1	   	  	   	  	   	  	   0.159	   86.3	  3498	   C>T	   rs1132899	   exon	  2	  (non-­‐synonymous)	   Pro36Leu	   0.476	   87.4	   0.223	   87.4	  3502	   C>T	   rs10423683	   exon	  2	  (Synonymous)	   Ser37Ser	   	  	   	  	   0.06	   87.4	  3546	   G>A	   rs12691089	   exon	  2	  (non-­‐synonymous)	   Gly52Asp	   0.006	   88.4	   	  	   	  	  3592	   C>T	   rs12691090	   exon	  2	  (synonymous)	   Asp67Asp	   	  	   	  	   0.027	   96.8	  3700	   G>A	   	  	   intron	  2	   	  	   	  	   	  	   0.005	   97.9	  3792	   G>A	   rs5165	   intron	  2	   	  	   	  	   	  	   0.017	   94.7	  3847	   T>C	   	  	   splice	  site	   	  	   0.011	   96.8	   	  	   	  	  3927	   T>G	   rs5167	   exon	  3	  (non-­‐synonymous)	   Leu96Arg	   0.339	   94.7	   0.472	   94.7	  3969	   A>C	   	  	   exon	  3	  (non-­‐synonymous)	   Lys110Tyr	   	  	   	  	   0.011	   97.9	  4012	   G>A	   	  	   exon	  3	  (non-­‐synonymous)	   Lys124Arg	   	  	   	  	   0.005	   95.8	  4154	   G>A	   rs12709884	   3’	  UTR	   	  	   	  	   	  	   0.115	   95.8	  4157	   G>A	   rs10425530	   3’	  UTR	   	  	   	  	   	  	   0.1	   94.7	  4533	   C>T	   	  	   3’	  flanking	  region	   	  	   	  	   	  	   0.011	   92.6	  4579	   G>A	   	  	   3’	  flanking	  region	   	  	   	  	   	  	   0.052	   91.6	  4628	   G>A	   rs12721063	   3’	  flanking	  region	   	  	   0.011	   94.7	   	  	   	  	  4661	   C>G	   rs2288912	   3’	  flanking	  region	   	  	   0.494	   91.6	   0.244	   88.4	  4746	   T>G	   rs2288911	   3’	  flanking	  region	   	  	   0.500	   93.7	   0.224	   89.5	  4844	   G>A	   	  	   3’	  flanking	  region	   	  	   	  	   	  	   0.107	   88.4	  4895	   G>A	   	  	   3’	  flanking	  region	  	   	  	   0.006	   91.6	   	  	   	  	  4912	   G>C	   	  	   3’	  flanking	  region	   	  	   	  	   	  	   0.006	   88.4	  4929-­‐4959	   dinucleotide	  repeats	   	   3’flanking	  region	   	   -­‐-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐-­‐	  
Variants with refSNPs ID represent previously reported variants and those present in both populations are 
highlighted in yellow. 
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Figure 3 Distribution of APOC4 Genetic Variants 
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3.1.1 Non-Hispanic Whites 
A total of 26 variants were identified in NHWs plus one dinucleotide microsatellite. Twelve of 
26 variants were previously reported in databases and 14 variants were new. Since the 
dinucleotide microsatellite was not fully analyzed, it is not included in the total number of 
ethnic-specific variants. Only 8 of these variants had MAF<1%, 5 variants had MAF 1-5% and 
13 variants had MAF ???????????????????????? ??????????? ??? ????? ?????????????? ???????? ??? ????
5’flanking region, 1 was in the 5’UTR, 10 were in introns, 1 was in the splice site, 3 variants 
were in exons, and 4 in the 3’flanking region. Three of 26 variants were indels (two small 
deletions and one large insertion) with the number of bases affected range was between 3-114 
bp. One deletion (92_94del3) was in the 5’flanking region, one insertion (150_151ins114) was in 
the 5’flanking region and one deletion (1325_1327del3) was in intron 1. There was one variant 
in the splice site, 3847 T>C. The 3 variants in the coding region were non-synonymous SNPs 
resulted in amino acid changes: 3498 C>T/ rs1132899 (Pro36Leu)/ MAF=0.476 was in exon 2, 
3546G>A/ rs12691089 (Gly52Asp)/ MAF=0.006 was in exon 2, and 3927T>G/ rs5167 
(Leu96Arg)/ MAF=0.339 was located in exon 3. 
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3.1.2 African Blacks 
A total of 51 variants were identified in African Black plus one dinucleotide microsatellite, 
including 4 indels. Twenty-three of the 51 identified variants were previously reported in 
databases, and 28 were new. Since the dinucleotide microsatellite was not fully analyzed, it is not 
included in the total number of ethnic-specific variants. Fifteen variants had MAF<1%, 15 had 
MAF 1-5%, and 21 had MAF ???????????????????????????????????????????????????????????????????
the 5’flanking region, 24 were located in introns, one was in the splice site, 6 were in exons, 2 
were in the 3’UTR, and 6 were in the 3’flanking region. Four out of 51 variants were indels (2 
deletions and 2 insertions) with number of bases affected range was between 1-114 bp. One 
deletion and one insertion were located in the 5’ flanking region (92_94del3, 150_151ins114), 
and additional one deletion and one insertion were located in intron 1 (1325_1327del3, 
1430_1431ins1). There was one variant in the splice site 1088 T>G. Among the 6 variants in the 
coding region 4 variants were non-synonymous, including two unreported SNPs. The two known 
non-synonymous variants were: 3498 C>T/ rs1132899 (Pro36Leu)/ MAF=0.223 was in exon 2 
and 3927 T>G/ rs5167 (Leu96Arg) / MAF=0.472 was in exon 3. The two new non-synonymous 
variants were observed only in Blacks: 3969A>C (Lys110Tyr) / MAF=0.011 was in exon 3 and 
4012 G>A (Lys124Arg)/ MAF=0.005was in exon 3. 
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3.1.3 APOC4 Annotated Sequence 
Variants identified in the APOC4 gene are depicted in a colored FASTA representation of 
APOC4 annotated reference sequence adopted from SeattleSNPs database 
(http://pga.gs.washington.edu/) with additional sequence (from 4,511-5,086) from CHIP 
database (dbSNPs build: 130) (http://snpper.chip.org/) in Figure 4. The annotated reference 
sequence was modified by including the identified variants in this study with population-specific 
variants representation. The dinucleotide microsatellite was not included in this annotated 
sequence. Variants identified in both populations (NHWs and African Blacks) (n=13) are 
depicted in RED font. Blue font used for variants identified in African Blacks population only 
(n=38) and Black font used for variants identified only in NHWs population (n=13). All variants 
that identified previously in database but not in our study had MAF<0.02 and depicted with 
Dark green font.  Yellow highlight is used for deletion (n=2) and blue highlight is used for 
bases flank the insertion (n=2) with the population-specific color font. Variants identified in 
Seattle and in our study include ref SNPs ID in addition to its position according to annotated 
Seattle reference sequence and allele change. The color code used in SeattleSNPs for the 
reference sequence is as follows: light grey for flanking regions and introns, green for UTR, dark 
blue for exons, purple for repeat regions, and light blue for regions not scanned in SeattleSNPs 
database. 
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GAGACGGAGT CTTGCTCTTT CGCCCAGGCT GGACTGCAGT GGCGCGATCT 50  | REPEAT  
CGGCTCAATG CAAGCTCCAC CTCCCAGGTT CACGCCATTC TCCTGCCTCA 100 | p.65[C>T]| 
p.92_94/rs12721101[delCCT]  
GCCTCCCGAG TAGCTAGGAC TACAGGCGCC TGCCACCACG CCTGGCTAAT 150 | p.108[G>A]| p.116[A>G] 
TTTTCATATT TTTAGTAGAG ATGGGGTTTC ACCGTGTTAG CCAAGATGGT 200 | P.150_151[ins114] 
CTCAATCTCC TGACCTCGTG ATCCGCCTGC CTCGGCCTCC CAAAGTGTTG 250 | p.204/rs4803773[A>G]| 
p.233[C>T]| p.245/[G>T]  
GGGTTACAGG CATGAGCCAC CGCGCCTGGC CAACAGCAAT GATCTTTGAG 300 | REPEAT 
CACCTATATT GCCAGTCTCC ACGGTAAGAG CTTTCTTCAT TTTTTGTTTT 350 | REPEAT  
GTTTTGTTTC AAGACAGAGT CTTGCTCTGT CACCCAGGCT GGAGTGCAGT 400 | p.368[A>G]   
GGTGTGATCG CGGCTCACTG CAGCCTTCAC TTCCCGGGTT CAAGCCATTC 450 | p.438[G>A] 
TCCTGCCTCA GCCTCCCAAG TAGCTGGGAT TACAGGCACG CATCACTACT 500 | p.489[C>T] 
TCTGGCTAAT TTTTGTATTT TTAGTAGGGA CAGGGTTTTT CACCATGTTG 550  
GCCAGGTTGG TCTCAAACTC CTGGCCTCAT ATGATCTGCC CACCTCGGCC 600  
TCCCAAAGTG CTGGGATTAC AGGCGTGAGC CACTGCGCCT TTCTTTGTAT 650 | REPEAT| p.636[C>T]| 
p.637/rs73558107[G>T]  
TTGTTCAAGT AATATACTGA AATATGTACT GTGCCTCCCA CTTTATGGAG 700  
GAGGAAACTG AGGCCAGCAA ATGAGGCTGT CATGGGAGGT GGAGACAGGA 750  
TTTGAACCTG CCTCAGTGCA GGAGGCTCAA GAGCCTCTGT CTTCTCTCAG 800 | p.757/rs12721105[C>A]  
GGCACTGTGT GGGAGGGTGA GAAGGAGGGA GGCCCACAGA GGCATGACCT 850  
CTGATTGCCA CTGTCACCTG GGCCCTGCTC TCTGAAGTCT CTGCCAAGCG 900 | p.870[G>A] 
GGGAGGTGGC CGGGGGAGGG CCCTGCTCTG TGCAGCCTCC CCTCCCCCGG 950  
CCCGCAGAGT TGAGCACAGA GGGACAGAGG CACGGAACCC CCAGAAATGT 1000 | Exon 1 | UTR| p.968[A>G]  
                                                   M   1 
CCCTCCTCAG AAACAGGCTC CAGGCCCTGC CTGCCCTGTG CCTCTGCGTG 1050  
S  L  L  R   N  R  L   Q  A  L   P  A  L  C   L  C  V  18  
CTGGTCCTGG CCTGCATTGG GGGTGAGAAG AAGTGGGTGG AGGGATGTGG 1100 | p.1088[T>G] 
 L  V  L   A  C  I  G                                  25 
GGCCCACACC TGGTGGGTGT GAGTGTGGCT GTGTGTCCTG TGGCTCTGTA 1150 | p.1130[T>C]| P.1150[A>G] 
GCCACGTGAG ACATGAGTAC GGAGTGTGTG CGTTTCATGG CGTGCGTATG 1200 | p.1192[G>A] 
CATGTGCGTG TCGGGGAGTG TGTGTGTCGG TGGCTGAGAG TGAAGTGTGA 1250 | p.1229[G>C] 
ATGTCACATT GGTACAAACT GGGATCATCT GTGTGTGTGC ACGTGCGTGC 1300  
GTGGAAGTGG GAGTATGCAG TCGTGGTAAA AAAGTGCATG TCTGTGTGCA 1350 | p.1325_1327[delGGT] 
TATGTGTATT TGTGTGCACC TGTCTCTCTG TGGGGTATGT GTGTGCAAAA 1400  
TATTTGAGTG TGTGGACATG TGTGAGGGGG TGAGTGTGTG CTGGTGTGTA 1450 | p.1430_1431[insG] 
CGTCTGTGTT TTGCATATGC ATTTTTTTTT TTTTTTTTGA GACGGAGTCT 1500 | REPEAT  
CACTCTGTCA CCCAGGCTGG AGTGCAGTGG TAGCAGTGGT GCGATCTTGG 1550  
CTCACTGCAT CATCCGCCTA CCCGTTTCAA GGGATTCTCC TGCCTCAGTC 1600  
TTCAGAGTAT TTGGGACTAC AGACACACGC CACCATGCCT GGCTAATTTT 1650 | REPEAT  
TTTTTTTTGA GACGGAGTCT CGCTCTGTTA CCCAGGCTGG AGTGCAGTGG 1700  
CGTGATCTTG GCTCACTGCA AGCTCCGCCT CCCGGGTTCA CGCCATTCTC 1750 | p.1702/rs12721102[G>A]| 
p.1719[C>A]| p.1733/rs12721111[C>T]  
CTGCCTCAGC CTCCCGAGTA GCTGGGACTA CAGGAGCCCA CCACCACGCC 1800  
TGGCTAATTT TTTGTATTTT TACTAGAGAC GGGGTTTCGC CGTGTTAGCC 1850 | p.1823[C>G] 
AGGATGGTCT CCATATCCTG ACCTCGTGAT CCGCCTGCCT CGGCCTTCCA 1900 | NOT SCANNED  
AAGTGCTAGG ATTATAGGCG TGAGCCACTG CGCCTGGCCA ATGCCTGGCT 1950 | REPEAT  
AATTTTTTTA TATTTTTGGT AGAGACAGGG TTTTGCCATG TTGCCCAGGC 2000  
TGGTCTTGAA ATCCTGACCT CAGGTGATCC GCCCGCCTTG GCCTCCCAAA 2050  
GTGCTGGGAT TACAGGCATG AGCCACCACG CCCGGCCATG TACTTTATGT 2100 | p.2063[C>G]| p.2099[G>T] 
TAAAATGGGA TCATATTCTA GATCAGCATT ATCCAGTAGA AATTTAAATT 2150  
TTTAATACAG GGCCAGGCAC GGTGGCTCAT GCCTGTAATC CCAGCACTTT 2200 | REPEAT  
CGGAGGCCGA GGCGGGTGGA TCGCAAGGTC AGGAGATTTG AGATCATCCT 2250  
GGCTAACAGA TGGGTAAAAA CCCATCTCTA CTAAAAATAC AAAAAATTAG 2300  
CCATGCATGG TGGCATGCGC CTGTAGTCCC AGCTACTCGG GAGGCTGAGG 2350  
CCGGAGAATC ACTTGAACCC GGGAGGCAGA GGTTGCAGTG AGCCGAGATC 2400  
GCGCCACTGC ATTCCAACCT GGGTGACAGA GCGAGACTCC GTCTGAAAAA 2450  
AAAAAAAAAT TTAACACGTA TGTAGACAAT GTGCAAGGCA CCATTCCATG 2500 | p.2467[C>T]| REPEAT  
TGCATCGTAT GTAGTAACTC TTAATTCTCA CGATAACCCT GAGGTAGATA 2550  
TTATTACCCC GTTCTACAAA AGGAGAAACA GTCCTGGGGA GACAGGATAA 2600 | p.2557[C>A]| 
p.2559/rs5155[C>T]  
  44 
GTCACCGGCC AAGGCACACA GCCAGCTACA TGTGGCCCCC GCGTGACGGC 2650 | p.2607[G>A]/rs5156| 
p.2623/rs5157[C>T] | p.2640/rs5158[C>T]| p.2641[G>A]  
TGGTCTCTGT AGGCGAGGCT TTGTCCAGAT GCGTGGGTAG AAGGTCTGGC 2700 | p.2678[G>C]|  
p.2683/rs12721109[G>A]  
CCGGAAAGAG GAACTGACAG CAAGGCTAAG CCAATGTCTG CCCCTGGGGG 2750 | p.2703/[G>T]  
CAGAAAGTCA CCTCCTGCTC TCCCTCCACT GTCCACAGAG GTAGCTCAGA 2800 | p.2753[G>A] | 
p.2767/rs12721107[G>T]  
CAGGGTGGGG GTCACAGGAG AACGAAGGGA GAAGGGGGTA GTTCCTGGGC 2850  
AGCAAAATCA GGTGGTGAAG GGAGGCATCA GAGGATGGCA ATTAGAGAGG 2900 | p.2886[T>C] 
CCATTAGAGG GGAACCACAG GCAGACAGGG TGACAGGAGG GACTACTGAC 2950  
ACAAGGTGAA GAGATGGCCC AGCCGGACGG GGTGGCTCAC ATCTGTAATC 3000 | REPEAT | 
p.2971/rs5159[A>G]  
CCAGCATTTT GGGAGCCCGA GGTGGGTGGA TCACTTGAGG TCAGGAGTTC 3050  
GAGGCCCCAA CATGGCAAAA CCCCATCTCT TCTAAAAATA CAAAAATTAG 3100  
CCGGGCATGA TGGCAGATGC CTGTAATCCC TGCTACTCGG GAGGCTGAGG 3150  
CAGGAAAATT GCCTGAATCC AGGAGGTGGA GGTTGCAATG AGACGAGATC 3200  
ATGACACTGC ACTCCACCCT GGGCAACAGA GCAAGAGACT GACTCTGTCT 3250 | p.3213/rs28616151[T>C] 
CATAAAAAAA AAGAAAAAAG AAAAAAAAAA AGAGATGGCT GATGGTTAAA 3300  
GAGGGGTTAG CGGTCAGGGG ACACATAAGG GTAAAGGCAG GAGGCAAGAG 3350 | p.3348[G>A] 
GACTGGCAGG GGGCTGCCCC TGGGCCACCG GGAGCGACAC AGGATGAGCA 3400 | p.3363[G>A]| 
p.3380/rs12721104[G>A]  
TGGAGGGAAA GGGAGAAGGG GATTCTAGGG TCCCAGCCTA CCCAAGTTGC 3450  
CCTCTGGTTC CACCTAGCAT GCCAGCCAGA GGCCCAGGAA GGAACCCCGA 3500 | Exon 2 | 
p.3498/rs1132899[C>T]  
                  A   C  Q  P  E   A  Q  E   G  T  P   36 
GCCCCCCACC AAAGCTAAAG ATGAGTCGCT GGAGCCTGGT GAGGGGCAGG 3550 | p.3502/rs10423683[C>T]| 
p.3546/rs12691089[G>A]  
S  P  P  P   K  L  K   M  S  R   W  S  L  V   R  G  R  53 
ATGAAGGAGC TGCTGGAGAC AGTGGTGAAC AGGACCAGAG ACGGGTGGCA 3600 | p.3592/rs12691090[C>T]  
 M  K  E   L  L  E  T   V  V  N   R  T  R   D  G  W  Q 70 
ATGGTTCTGG TGAGGGTGTG CTGGGCTGGG TGGTGGGAGG GGACTCCTGG 3650 | REPEAT  
  W  F  W                                              73 
GTCTGAGGGA GGAGGGGCTG GGGCCTGGAC CCCTGAGTCT CAGGGAGGAG 3700 | p.3700[G>A] 
GAAAGGGTGG GAGTGGGGCT GTGACCCCTA GGTCTGGGAG GAGTGGAGGG 3750  
TTAGAGCTGA GAGCAGGAAC TCCTAGGTCA CAGAGAGGAG CGGATAAATG 3800 | p.3792/rs5165[G>A] 
GGGCAGAGAA CACCTGGGGA GAGCTGGGGC CTCCACTGTG ATGTCCTCTC 3850 | p.3847[T>C] 
TCCTGTAGGA GCCCGAGCAC CTTCCGGGGC TTCATGCAGA CCTACTATGA 3900 | Exon 3  
           S  P  S  T   F  R  G   F  M  Q   T  Y  Y  D 87 
CGACCACCTG AGGGACCTGG GTCCGCTCAC CAAGGCCTGG TTCCTCGAAT 3950 | p.3927/rs5167[T>G]  
  D  H  L   R  D  L   G  P  L  T   K  A  W   F  L  E   103 
CCAAAGACAG CCTCTTGAAG AAGACCCACA GCCTGTGCCC CAGGCTTGTC 4000 | p.3969[A>C] 
S  K  D  S   L  L  K   K  T  H   S  L  C  P   R  L  V  120 
TGTGGGGACA AGGACCAGGG TTAAAATGTT CATAAAAGCC AGGTGTGGTT 4050 | UTR | REPEAT| 
p.4012[G>A]  
 C  G  D   K  D  Q  G                                  127 
GTGGCGGGTG CCTGTAGTCC CAGCTACTCA GGAGGCTGAG GTAGGATGAT 4100  
GGCTTGAGCC CAGGAGTTCG AGACCAGCCT GGGCAACACA GCGAGATCTC 4150  
TTGGGGGTAA AACAAAAAGA AAAAAAAAAG TTCATACTTC TCCAATAAAT 4200 | p.4154/rs12709884[G>A]| 
p.4157/rs10425530[G>A] 
AAAGTCTCAC CTGTGTCCCT GTCTGGATCC TTCCCCAGTG TGGCCAGAAA 4250  
AAAACCCACC CCACTGCCTC CCAGGAATCA ATGAGTAGAA GAGGTGACAC 4300  
CTGATGGGGA AGGAAGAGTA GGGAGGTCGG GAAGGGTATC AAGGAATAAC 4350 | p.4346[A>T]  
ACCCTATTGT GGGCTTGCGG AGAATGGGGG ACTTCAAGGC GTGTCAGTTT 4400  
CAGGAGGGTG AGGGCAGGAG CGTGGGTGGA GTCAGCAGGT CCCCATGATG 4450  
GCCCTCACTG AGAGCTTCGC CCTTGTCTCC TACAAGCTCT GACTCCATTC 4500  
CCAGTGGGCA CCCAGCACCT CCAACCCCTC CACAGCCCCC AACCCAGCCT 
CTGTCGGAGG CGAATTCTCA GAGTGAGGGT TCCCTGTCAC TTGAGAGAAG 
4550 | p.4533[C>T] 
GTTCCCTGTG ACGTGACCTT GGGGGACGTC ATTGCCCTTT CTGTCCCCAC 
4600 | p.4579[G>A] 
CCACCCCCTC CGCAGTTCTG TTGGCCAGGA CTTTGGCCTA GACAAAGGAT 
4650 | p.4628/rs12721063[G>A] 
GGGGGTTGTG GCTGTGGAGC GGAAGTGGGT CTCAACCACT ATAAATCCTC 
4700 | p.4661/rs2288912[C>G] 
TCTGTGCCCG TCCGGAGCTG GTGAGGACAG CCTGCCAGAG TCTGGTAAGA 
4750 | p.4746/rs2288911[T>G] 
AAGGGACTCA GGGTGCGGGG ACAGGGGGGC GTCAGCAGGG AGAGGGCAAA 
4800 
GATCGATAAA GCAGGAATTT TAAGAGGCAC AATATTAGAA GCCCGTGTTG 
4850 | p.4844[G>A] 
4900 | p.4895[G>A] 
  45 
GAACCATGAC TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG 
TGTGAGAGAG AGAGAGAGGG AGATGGAGTC TCGCTATGTA GCCCAGGCTA 
4950 | p.4912[G>C] 
GACTCAAACT CCTGGGCTCA AGCAATCCTC CTGCCTCAGC CTCCCCAGTA 
5000 
GCTGGGACTA CAGGTGCACC ACCACACTCC ACAAAT                
5050 
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Figure 4 APOC4 Annotated Sequences 
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3.2 DISTRIBUTION OF APOC4 VARIANTS IN HIGH AND LOW HDL-C GROUPS 
3.2.1 Non-Hispanic Whites 
Of the 26 variants identified in this study in NHWs, 13 had MAF<5%, and 13 had MAF ??????
Among the fourteen variants that are identified in our study but they were not previously 
reported in other databases (Seattle and CHIP), the MAF range was 0.005-0.259. The 4 common 
variants that have not been reported previously are: (108G>A/MAF=0.259, 5’flanking region), 
(150_151ins114/MAF=0.256, 5’flanking region), (1325_1327del3/MAF=0.147, intron 1), and 
(1823C>G/MAF=0.187, intron 1). The108C>G and 150_151ins114 variants were in complete 
LD with previously reported 92_94del3. None of the thirteen common variants showed 
significant difference between low and high HDL-C group. Table 9 shows the allele distribution 
of common variants among low and high HDL-C groups. Among relatively uncommon or rare 
variants (MAF<5%), while 8 variants were present only in low HDL-C group, only 2 variants 
were present in high HDL-C group. Three variants were present in both low and high HDL-C 
groups. Table 10 shows the distribution of rare or relatively uncommon variants among low and 
high HDL-C groups. The number of individuals having a minimum of one rare variant was 
higher in the low HDL-C group (15/48, 31.3%) compared to the high HDL-C group (5/47, 
10.6%). Of the exonic variants, one non-synonymous variant located in exon 2 (rs12691089 
[Gly52Asp]/ MAF=0.011) was present only in the low HDL-C group. Rare variants genotypes 
include individuals with less than 100% genotype call rate, which might underestimate the 
magnitude in the difference of allele distribution among low and high HDL-C group.  
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Table 9 Distribution of APOC4 Common Variants in High and Low HDL-C Group in NHWs  
APOC4	  variant	  Position	   Base	  Change	   Ref	  SNP	  ID	   Location	   amino	  acid	  change	   all	  MAF	  %	   Frequency	  in	  high	  HDL-­‐C	   Frequency	  in	  low	  HDL-­‐C	  	   P	  value	  92_94	   del3	   rs12721101	   5’	  flanking	  region	   	  	   0.259	   0.262	   0.256	   0.926	  108	   G>A	   	  	   5’flanking	  region	   	  	   0.259	   0.262	   0.256	   0.926	  150_151	   ins114	   	  	   5’flanking	  region	   	  	   0.256	   0.262	   0.250	   0.860	  204	   A>G	   rs4803773	   5’flanking	  region	   	  	   0.235	   0.212	   0.261	   0.565	  1325_1327	   del3	   	  	   Intron	  1	   	  	   0.147	   0.138	   0.154	   0.740	  1733	   C>T	   rs12721111	   Intron	  1	   	  	   0.263	   0.276	   0.250	   0.709	  1823	   C>G	   	  	   Intron	  1	   	  	   0.187	   0.191	   0.183	   0.897	  2623	   C>T	   rs5157	   Intron	  1	   	  	   0.477	   0.436	   0.489	   0.329	  2640	   C>T	   rs5158	   Intron	  1	   	  	   0.153	   0.159	   0.149	   0.860	  3498	   C>T	   rs1132899	   exon	  2	  (non-­‐synonymous)	   Pro36Leu	   0.476	   0.423	   0.477	   0.200	  3927	   T>G	   rs5167	   exon	  3	   Leu96Arg	   0.339	   0.372	   0.309	   0.368	  4661	   C>G	   rs2288912	   3’	  flanking	  region	   	  	   0.494	   0.489	   0.478	   0.657	  4746	   T>G	   rs2288911	   3’	  flanking	  region	   	  	   0.5	   0.476	   0.478	   0.544	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Table 10 Distribution of APOC4 Relatively Uncommon and Rare Variants in Low and High HDL-C 
Groups in NHWs 
 
APOC4  variant  
Position  
Base  
Change   Ref  SNP  ID   Location  
All  MAF  
%  
MAF%  high  
HDL-­‐C  
MAF%  low  
HDL-­‐C  
116   A>G        5’flanking  region   0.007   0.000   0.013  
636   C>T        5’  flanking  region   0.005   0.000   0.011  
870   G>A        5’flanking  region   0.005   0.011   0.000  
968   A>G        5’  UTR   0.038   0.011   0.062  
1150   A>G        intron  1   0.005   0.011   0.000  
1229   G>C        intron  1   0.011   0.000   0.021  
2063   C>G        intron  1   0.005   0.000   0.011  
2557   C>A        intron  1   0.006   0.000   0.011  
2683   G>A   rs12721109   intron  1   0.011   0.012   0.011  
3546   G>A   rs12691089   exon  2  (non-­‐synonymous)   0.006   0.000   0.011  
3847   T>C        splice  site   0.011   0.000   0.021  
4895   G>A        3’  flanking  region     0.006   0.000   0.011  
4628   G>A   rs12721063   3’  flanking  region   0.011   0.012   0.011  
Yellow highlighted variants represent variants that were uniquely present in low HDL-C group, while green 
highlighted variants represent variants that were uniquely present in high HDL-C group. 
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3.2.2 African Blacks 
Out of 51 variants identified in Blacks, 21 had MAF ????????????????? ????????????????????
variants that were identified in our study but they were not previously reported in other databases 
(Seattle and CHIP), the MAF range was 0.005-0.283. In addition to 108G>A, 150_151ins114 
and 1823C>G, two common variants were located in the 3’flanking region, 
(4579G>A/MAF=0.052 and 4844G>A/MAF=0.107) were not identified previously. No 
statistically significant difference was found in the allele frequencies of common variants 
between low and high HDL-C groups. Two variants 150_151ins114 and 4579G>A showed 
borderline associations with respective p-value 0.094, 0.081. Table 11 shows the distribution of 
common variants in low and high HDL-C groups. Of the 30 relatively uncommon and rare 
variants (MAF<5%), 10 were present in the low HDL-C group and 7 were present in the high 
HDL-C group. Table 12 shows the distribution of rare and relatively uncommon variants in low 
and high HDL-C groups. The number of individuals having a minimum of one rare or less 
common variant was quite comparable in both groups with a little bit higher in the high HDL-C 
group (26/48, 54%) than in the low HDL-C group (22/47, 46%). Of the exonic variants, one non-
synonymous variant located in exon 3 4012G>A (Lys124Arg) was present only in the low HDL-
C group. 
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Table 11 Distribution of APOC4 Common Variants in Low and High HDL-C Groups in Blacks APOC4	  variants	  Position	   Base	  Change	   Ref	  SNP	  ID	   Location	   Amino	  acid	  change	   all	  MAF	  %	   Frequency	  in	  high	  HDL-­‐C	  group	   Frequency	  in	  low	  HDL-­‐C	  group	  
p-­‐value	  
92_94	   Del3	   rs12721101	   5’	  flanking	  region	   	  	   0.262	   0.209	   0.321	   0.106	  108	   G>A	   	  	   5’	  flanking	  region	   	  	   0.262	   0.209	   0.321	   0.106	  150_151	   Ins114	   	  	   5’	  flanking	  region	   	  	   0.283	   0.228	   0.341	   0.094	  204	   A>G	   rs4803773	   5’	  flanking	  region	   	  	   0.233	   0.250	   0.216	   0.589	  757	   C>A	   rs12721105	   5’	  flanking	  region	   	  	   0.054	   0.064	   0.043	   0.538	  1733	   C>T	   rs1271111	   intron	  1	   	  	   0.244	   0.228	   0.262	   0.602	  1823	   C>G	   	  	   intron	  1	   	  	   0.203	   0.238	   0.156	   0.220	  2559	   C>T	   rs5155	   intron	  1	   	  	   0.088	   0.067	   0.109	   0.317	  2623	   C>T	   rs5157	   intron	  1	   	  	   0.163	   0.163	   0.163	   1.000	  2971	   A>G	   rs5159	   intron	  1	   	  	   0.150	   0.152	   0.148	   0.933	  3213	   T>C	   rs28616151	   intron	  1	   	  	   0.056	   0.064	   0.048	   0.639	  3380	   G>A	   rs12721104	   intron	  1	   	  	   0.159	   0.151	   0.167	   0.786	  3498	   C>T	   rs1132899	   exon	  2	  (non-­‐synonymous)	   Pro36Leu	   0.223	   0.227	   0.218	   0.886	  3502	   C>T	   rs10423683	   exon	  2	  (Synonymous)	   Ser37Ser	   0.060	   0.068	   0.051	   0.648	  3927	   T>G	   rs5167	   exon	  3	  (non-­‐synonymous0	   Leu96Arg	   0.472	   0.554	   0.500	   0.465	  4154	   G>A	   rs12709884	   3’	  UTR	   	  	   0.115	   0.106	   0.125	   0.694	  4157	   G>A	   rs10425530	   3’	  UTR	   	  	   0.100	   0.106	   0.093	   0.765	  4579	   G>A	   	  	   3’	  flanking	  region	   	  	   0.052	   0.023	   0.081	   0.081	  4661	   C>G	   rs2288912	   3’	  flanking	  region	   	  	   0.244	   0.267	   0.220	   0.470	  4746	   T>G	   rs2288911	   3’	  flanking	  region	   	  	   0.224	   0.250	   0.198	   0.413	  4844	   G>A	   	  	   3’	  flanking	  region	   	  	   0.107	   0.110	   0.105	   0.915	  
Yellow highlighted variants have marginally significant p-value 
 
 
 
 
 
 
  51 
 
Table 12 Distribution of APOC4 Relatively Uncommon and Rare Variants in Low and High HDl-C 
Groups in Blacks 
 
APOC4	  
variants	  
Base	  
Change	   Ref	  SNP	  ID	   Function	   all	  MAF	  %	  
MAF%	  low	  
HDL-­‐C	  group	  
MAF%	  high	  
HDL-­‐C	  
group	  
65	   C>T	   	  	   5’	  flanking	  region	   0.007	   0.015	   0.000	  
233	   C>T	   	  	   5’	  flanking	  region	   0.006	   0.011	   0.000	  
245	   G>T	   	  	   5’	  flanking	  region	   0.006	   0.011	   0.000	  
368	   A>G	   	  	   5’	  flanking	  region	   0.011	   0.011	   0.011	  
438	   G>A	   	  	   5’	  flanking	  region	   0.006	   0.011	   0.000	  
489	   C>T	   	  	   5’	  flanking	  region	   0.017	   0.023	   0.011	  
637	   G>T	   rs73558107	   5’	  flanking	  region	   0.043	   0.043	   0.042	  
1088	   T>G	   	  	   intron	  1	   0.006	   0.012	   0.000	  
1130	   T>C	   	  	   intron	  1	   0.005	   0.000	   0.011	  
1192	   G>A	   	  	   intron	  1	   0.006	   0.000	   0.011	  
1325_1327	   del3	   	  	   intron	  1	   0.047	   0.023	   0.073	  
1430_1431	   ins1	   	  	   intron	  1	   0.033	   0.033	   0.033	  
1702	   G>A	   rs12721102	   intron	  1	   0.006	   0.000	   0.011	  
1719	   C>A	   	  	   intron	  1	   0.006	   0.000	   0.011	  
2099	   G>T	   	  	   intron	  1	   0.011	   0.011	   0.010	  
2467	   C>T	   	  	   intron	  1	   0.017	   0.011	   0.023	  
2607	   G>A	   rs5156 intron	  1	   0.016	   0.011	   0.021	  
2640	   C>T	   rs5158	   intron	  1	   0.033	   0.022	   0.043	  
2641	   G>A	   	  	   intron	  1	   0.005	   0.011	   0.000	  
2678	   G>C	   	  	   intron	  1	   0.005	   0.011	   0.000	  
2767	   G>T	   rs12721107	   intron	  1	   0.017	   0.000	   0.035	  
3348	   G>A	   	  	   intron	  1	   0.006	   0.000	   0.012	  
3363	   G>A	   	  	   intron	  1	   0.043	   0.038	   0.048	  
3592	   C>T	   rs12691090	   exon	  2	  (non-­‐synonymous)	   0.027	   0.011	   0.042	  
3700	   G>A	   	  	   intron	  2	   0.005	   0.000	   0.010	  
3792	   G>A	   rs5165	   intron	  2	   0.017	   0.012	   0.000	  
3969	   A>C	   	  	   exon	  3	  (non-­‐synonymous)	   0.011	   0.011	   0.011	  
4012	   G>A	   	  	   exon	  3	  (non-­‐synonymous)	   0.005	   0.011	   0.000	  
4533	   C>T	   	  	   3’	  flanking	  region	   0.011	   0.011	   0.011	  
4912	   G>C	   	  	   3’	  flanking	  region	   0.006	   0.120	   0.000	  
Yellow highlighted variants represent variants that were uniquely present in low HDL-C group, while green 
highlighted variants represent variants that were uniquely present in high HDL-C group. 
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3.3 LD AND TAGGER ANALYSIS OF APOC4 VARIANTS 
3.3.1 Non-Hispanic Whites 
LD and tagger analysis (by using Haploview software) of 13 common variants with MAF ??
0.049 and r2 
 
cutoff 0.9 identified 6 tag-SNPs Bins in NHWs (Table 13). Figure 5 shows LD plot 
of common variants identified in our study in NHWs. 
 
Table 13 Tagger Results of Common Variants Identified in NHWs by Using Haploview 
Bin Test Alleles Captured Genotyped SNPs 
1 4746 4746, 204,3498 , 2623 3498 (rs1132899) , 4661 2623 (rs5157) 
2 108 92_94del3, 108, 150_151ins114 -------- 
3 1325_1327del3 1325_1327del3, 2640 (rs5158) 2640  
4 1733 1733 -------- 
5 3927 3927(rs5167) 3927 
6 1823 1823 --------- 
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Figure 5 LD Plot of Common Variants Identified in NHWs 
 
3.3.2 African Blacks 
LD and tagger function from haploview analysis by using r2
 
 cutoff 0.9 of 21 common variants 
identified in our study in Blacks yielded 15 Bins of tag-SNPs (Table 14). Figure 6 illustrates the 
LD pattern of common variants in Black. 
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          Table 14 Tagger Results of Common Variants Identified in Blacks 
Bin Test Alleles Captured Genotyped SNPs 
1 92_94del3 92_94del3,150_151ins114,108 ---------- 
2 3502 3502,3213,757 ---------- 
3 3380  2971, 3380(rs12721104) 3380  
4 204 204, 3498 (rs1132899) 3498  
5 4579 4579 ---------- 
6 4154 4154 ---------- 
7 4746 4746 ---------- 
8 1823 1823 ---------- 
9 2559 2559 (rs5155) 2559  
10 4157 4157(rs10425530) 4157  
11 4661 4661 ---------- 
12 2623 2623(rs5157) 2623  
13 4844 4844 ---------- 
14 3927 3927(rs5167) 3927  
15 1733 1733 ---------- 
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Figure 6 LD Plot of Common Variants Identified in Blacks 
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3.4 GENOTYPING COMMON VARIANTS IN THE TOTAL NHW AND BLACK 
SAMPLES 
We genotyped seven common variants in Blacks and four common variants in NHWs using 
premade TaqMan SNPs genotyping assays. Genotyping features for all genotyped SNPs are 
summarized in Table 15. 
 
Table 15 TaqMan SNPs Genotyping Features 
Ref SNP ID *Position location Hapmap MAF% CEU               YRI 
NHWs 
Call Rate       HWE p-value 
African Blacks 
Call Rate    HWE p-value 
rs1132899 3498 missense (T) 0.392 (T) 0.291 0.9919 0.655 0.986 0.699 
rs5158 2640 intron (T) 0.092 (T) 0.025 0.9919 0.919 0.979 1.000 
rs5157 2623 intron (C) 0.448 (T) 0.203 0.9967 0.824 0.97 0.772 
rs5155 2559 intron (T) 0.000 (T) 0.067 ----- ------ 0.9809 1.000 
rs10425530 4157 3’UTR (A) 0.000 (A) 0.100 ----- ------ 0.973 0.775 
rs5167 3927 intron (G) 0.328 (G) 0.404 0.9919 0.266 0.9809 0.549 
rs12721104 3380 missense (A) 0.000 (A) 0.086 ----- ------ 0.9733 1.000 
* Positions according to Seattle ref sequence. 
 
 
None of the variants deviated from HWE (p-value >0.05) in either sample. LD pattern of 
the common variants screened in the total NHW and Black samples were repeated which yielded 
similar pattern of LD as seen in subset of the sequenced individuals. Figure 7 and Figure 8 show 
LD pattern of common variants screened in the entire NHW and Black samples, respectively.  
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Figure 7 LD Plot of Common Variants Screened in the Total NHW Sample 
 
 
 
Figure 8 LD Plot of Common Variants Screened in the Total Black Sample 
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3.4.1 Association Analysis of the Common Variants Genotyped in the Total NHW and 
Black Samples  
Table 16 and Table 17 show the genotype count, covariate adjusted mean (for each genotype) for 
four lipid traits (cholesterol, HDL-C, LDL-C and TG), and adjusted p-value for each variant 
genotyped in the total NHW and Black samples, respectively. The variation in individual number 
is a factor of genotype data and lipid profile availability. Both additive and dominant models 
were used in the association analysis. No statistically significant association was found between 
Tag-SNPs genotyped and lipid traits in NHWs. We checked the variants that had significant 
association in African Blacks: rs5158 and rs5167. Although no significant p-values were 
observed for rs5158 (intron 1, MAF=0.153) with TG (p=0.148) and for rs5167 (exon 3, 
MAF=0.339) with LDL-C (p=0.127), trend in lipid trait was observed with minor allele 
heterozygosity. In the Black samples, significant association was observed between rs5158 
(intron 1, MAF=0.033) and TG (p=0.030).  Borderline associations were between rs5167 (exon 
3, MAF=0.472) and LDL-C (p=0.0615), rs1132899 (exon 2, MAF=0.233) and total Cholesterol 
(p=0.091), and rs10425530 (3’UTR, MAF=0.1) and HDL-C (p=0.099). 
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Table 16 Association Analysis of Common SNPs Screened in the Total NHW Sample 
rs5158  
Lipid  Profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
Cholesterol  
Additive  
CC  (456)   218.75±  1.98   0.167  
CT  (146)   212.61±  3.34       
TT  (11)   217.93±12.07       
Dominant  
CC  (456)   218.76±  1.97   0.121  
CT/TT  (157)   212.98±  3.22       
*HDL-­‐C  
Additive  
CC  (456)   50.18±  0.60   0.159  
CT  (149)   50.54±  1.01       
TT  (11)   59.52±  3.69       
Dominant  
CC  (456)   50.19±  0.61   0.423  
CT/TT  (160)   51.16±  0.96       
LDL-­‐C  
Additive  
CC  (451)   140.08±  1.84   0.224  
CT(147)   136.12±  3.08       
TT(11)   133.67±  11.15       
Dominant  
CC(451)   140.08±  1.84   0.229  
CT/TT  (158)   135.94±  2.97       
*TG  
Additive  
CC  (454)   144.64±  3.30   0.148  
CT(148)   136.15±  5.54       
TT(11)   124.40±  20.14       
Dominant  
CC  (454)   144.63±  3.3   0.183  
CT/TT  (159)   135.33±  5.34       
rs1132899  
Lipid  Profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
Cholesterol  
Additive  
CC  (158)   218.45±  3.23   0.997  
CT  (313)   216.17±  2.34       
TT  (142)   218.58±  3.44       
Dominant  
CC  (158)   218.44±  3.32   0.680  
CT/TT  (455)   216.92±  1.97       
*HDL-­‐C  
Additive  
CC  (159)   51.33±  0.98   0.538  
CT  (315)   49.84±  0.71       
TT  (142)   50.37±  1.05       
Dominant  
CC  (159)   51.33±  0.98   0.277  
CT/TT  (457)   50.0±  0.60       
LDL-­‐C  
Additive  
CC  (158)   139.25±  2.99     0.989  
CT  (311)   139.09±  2.17       
TT  (140)   139.20±  3.21       
Dominant  
CC  (158)   139.25±  2.99   0.971  
CT/TT  (451)   139.12±  1.83       
*TG  
Additive  
CC  (159)   139.61±  5.33   0.290  
CT  (313)   141.31±  3.87       
TT  (141)   147.16±  5.71       
Dominant  
CC  (159)   139.58±  5.32   0.466  
CT/TT  (454)   143.29±  3.26       
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Table 16 (Continued) 
rs5157  
Lipid  Profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
Cholesterol  
Additive  
CC  (153)   216.45±  3.27   0.903  
CT  (312)   217.77±  2.35       
TT  (151)   217.00±  3.33       
Dominant  
CC  (153)   216.45±  3.27   0.774  
CT/TT  (463)   217.52±  1.95       
*HDL-­‐C  
Additive  
CC  (154)   51.14±  1.00   0.595  
CT  (314)   50.06±  0.72       
TT  (151)   50.23±  1.02       
Dominant  
CC  (154)   51.14±  1.00   0.414  
CT/TT  (465)   50.11±  0.60       
LDL-­‐C  
Additive  
CC  (153)   137.55±  3.02   0.903  
CT  (310)   140.32±  2.18       
TT  (149)   138.02±  3.10       
Dominant  
CC  (153)   137.56±  3.02   0.559  
CT/TT  (459)   139.58±  1.82       
*TG  
Additive  
CC  (154)   138.98±  5.43   0.322  
CT  (312)   142.11±  3.91       
TT  (150)   145.74±  5.56       
Dominant  
CC  (154)   138.97±  5.43   0.390  
CT/TT  (462)   143.29±  3.26       
rs5167  
Lipid  Profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
Cholesterol  
Additive  
TT  (245)   214.52±  2.60   0.123  
TG  (296)   218.45±  2.44       
GG  (72)   221.92±  4.74       
Dominant  
TT  (245)   214.53±  2.60   0.162  
TG/GG  (368)   219.16±  2.18       
*HDL-­‐C  
Additive  
TT  (247)   50.74±  0.79   0.770  
TG  (297)   49.74±  0.74       
GG  (72)   51.10±  1.44       
Dominant  
TT  (247)   50.75±  0.79   0.500  
TG/GG  (369)   50.02±  0.66       
LDL-­‐C  
Additive  
TT  (244)   136.23±  2.41   0.127  
TG  (293)   140.77±  2.27       
GG  (72)   142.20±  4.38       
Dominant  
TT  (244)   136.24±  2.41   0.117  
TG/GG  (365)   141.07±  2.03       
*TG  
Additive  
TT  (245)   142.50±  4.43   0.976  
TG  (296)   141.92±  4.06       
GG  (72)   144.30±  7.91       
Dominant  
TT  (245)   142.51±	  4.33	     0.964  
TG/GG  (368)   142.41±	  3.64     
*  Log transformed value. 
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Table 17 Association Analysis of Common SNPs Screened in the Total Black Sample 
rs1132899  
Lipid  profile   Model   Genotype(count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
CC  (430)   172.89±  1.80   0.389  
CT  (280)   178.62±  2.25       
TT  (39)   166.37±  5.87       
Dominant  
CC  (430)   172.92±  1.80   0.092  
CT/TT  (319)   177.15±  2.12       
**HDL-­‐C  
Additive  
CC  (427)   48.75±  0.61   0.656  
CT  (279)   48.85±  0.76       
TT  (39)   46.91±  1.99       
Dominant  
CC  (427)   48.76±  0.61   0.907  
CT/TT  (318)   48.62±  0.72       
**LDL-­‐C  
Additive  
CC  (432)   109.98±  1.60   0.402  
CT  (281)   115.13±  1.99       
TT  (39)   105.15±  5.22       
Dominant  
CC  (432)   110.00±  1.60   0.106  
CT/TT  (320)   113.94±  1.88       
*TG  
Additive  
CC  (437)   69.29±  1.59   0.987  
CT(281)   69.64±  1.99       
TT  (40)   70.31±  5.15       
Dominant  
CC  (437)   69.29±  1.59   0.918  
CT/TT  (321)   69.72±  1.87       
rs5158  
Lipid  profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
CC  (712)   174.63±  1.45   0.955  
CT  (32)   173.76±  6.46       
TT  (0)            
Dominant  
CC  (712)   174.63±  1.45   0.955  
CT/TT  (32)   173.76±  6.46       
**HDL-­‐C  
Additive  
CC  (708)   48.68±  0.49   0.564  
CT  (32)   47.64±  2.19       
TT  (0)            
Dominant  
CC  (708)   48.68±  0.49   0.564  
CT/TT  (32)   47.64±  2.19       
**LDL-­‐C  
Additive  
CC  (716)   111.47±1.28   0.450  
CT  (31)   115.41±5.84       
TT  (0)            
Dominant  
CC  (716)   111.47±  1.28   0.450  
CT/TT  (31)   115.41±  5.84       
*TG  
Additive  
CC  (721)   69.88±  1.27   0.031  
CT  (32)   57.65±  5.70       
TT  (0)            
Dominant  
CC  (721)   69.88±  1.27   0.031  
CT/TT  (32)   57.65±  5.70       
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Table 17 (Continued) 
rs5157  
Lipid  profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
CC  (503)   173.50±  1.70   0.324  
CT  (215)   178.00±  2.57       
TT  (20)   167.71±  8.24       
Dominant  
CC  (503)   173.51±  1.70   0.155  
CT/TT  (235)   177.11±  2.46       
**HDL-­‐C  
Additive  
CC  (500)   48.62±  0.57   0.765  
CT  (214)   49.36±  0.86       
TT  (20)   43.49±  2.77       
Dominant  
CC  (500)   48.63±  0.57   0.766  
CT/TT  (234)   48.85±  0.83       
**LDL-­‐C  
Additive  
CC  (503)   110.59±  1.51   0.301  
CT  (218)   114.31±  2.27       
TT  (20)   109.12±  7.32       
Dominant  
CC  (503)   110.59±  1.51   0.194  
CT/TT  (238)   113.87±  2.17       
*TG  
Additive  
CC  (509)   69.00±  1.48   0.795  
CT  (217)   69.65±  2.25       
TT  (21)   73.23±  7.06       
Dominant  
CC  (509)   69.00±  1.48   0.884  
CT/TT  (238)   69.97±  2.15       
rs5155  
Lipid  profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
CC  (608)   175.22±  1.53   0.153  
CT  (131)   172.20±  3.19       
TT  (6)   148.85±  14.73       
Dominant  
CC  (608)   175.21±  1.53   0.267  
CT/TT  (137)   171.15±  3.12       
**HDL-­‐C  
Additive  
CC  (604)   48.78±  0.52   0.384  
CT  (131)   48.64±  1.09       
TT  (6)   38.80±  5.02       
Dominant  
CC  (604)   48.78±  0.52   0.650  
CT/TT  (137)   48.20±  1.06       
**LDL-­‐C  
Additive  
CC  (613)   111.97±  1.37   0.240  
CT  (129)   109.61±  2.87       
TT  (6)   95.56±  13.17       
Dominant  
CC  (613)   111.96±  1.37   0.327  
CT/TT  (135)   108.97±  2.81       
*TG  
Additive  
CC  (616)   69.80±  1.37   0.534  
CT  (132)   68.87±  2.87       
TT  (6)   72.10±  13.27       
Dominant  
CC  (616)   69.80±  1.37   0.495  
CT/TT  (138)   69.01±  2.80       
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                          Table  17  (Continued)  
rs10425530  
Lipid  profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
GG  (582)   174.82±  1.59   0.582  
GA  (149)   176.07±  3.05       
AA  (8)   152.37±  13.13       
Dominant  
GG  (582)   174.81±  1.60   0.854  
GA/AA  (157)   174.92±  2.99       
**HDL-­‐C  
Additive  
GG  (581)   48.24±  0.54   0.187  
GA  (146)   50.34±  1.04       
AA  (8)   45.01±  4.44       
Dominant  
GG  (581)   48.24±  0.54   0.099  
GA/AA  (154)   50.07±  1.02       
**LDL-­‐C  
Additive  
GG  (584)   112.12±  1.42   0.490  
GA  (150)   112.04±  2.71       
AA  (8)   94.23±  11.69       
Dominant  
GG  (584)   112.12±  1.42   0.700  
GA/AA  (158)   111.17±  2.65       
*TG  
Additive  
GG  (590)   69.68±  1.40       
GA  (151)   68.56±  2.68   0.594  
AA  (8)   67.19±  11.61       
Dominant  
GG  (590)   69.68±  1.40   0.665  
GA/AA  (159)   68.50±  2.62       
rs12721104  
Lipid  profile   Model   Genotype  (count)   mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
GG  (553)   174.64±  1.63   0.833  
GA  (173)   175.22±  2.81       
AA  (13)   168.34±  10.10       
Dominant  
GG  (553)   174.63±  1.63   0.964  
GA/AA  (186)   174.72±  2.71       
**HDL-­‐C  
Additive  
GG  (549)   48.75±  0.55   0.357  
GA  (173)   48.66±  0.94       
AA  (13)   42.96±  3.39       
Dominant  
GG  (549)   48.73±  0.55   0.639  
GA/AA  (186)   48.25±  0.91       
**LDL-­‐C  
Additive  
GG  (557)   111.58±  1.45   0.980  
GA  (172)   112.15±  2.52       
AA  (13)   109.50±  9.02       
Dominant  
GG  (557)   111.57±  1.45   0.934  
GA/AA  (185)   111.96±  2.42       
*TG  
Additive  
GG  (560)   68.73±  1.44   0.187  
GA  (175)   71.43±  1.49       
AA  (13)   79.72±  8.99       
Dominant  
GG  (560)   68.75±  1.44   0.225  
GA/AA  (188)   72.02±  2.40       
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                            Table  17  (Continued)  
rs5167  
Lipid  profile   Model   Genotype  (count)   Mean  ±  SE   P-­‐value  
*Cholesterol  
Additive  
TT  (219)   177.28±  2.52   0.117  
TG  (361)   174.96±  1.99       
GG  (165)   171.93±2.88       
Dominant  
TT  (219)   177.28±  2.52   0.195  
TG/GG  (526)   173.99±  1.66       
**HDL-­‐C  
Additive  
TT  (219)   48.21±  0.85   0.665  
TG  (359)   48.85±  0.68       
GG  (163)   48.70±  0.98       
Dominant  
TT  (219)   48.21±  0.85   0.533  
TG/GG  (522)   48.81±  0.56       
**LDL-­‐C  
Additive  
TT  (220)   114.85±  2.24   0.062  
TG  (363)   112.06±  1.77       
GG  (165)   108.47±  2.57       
Dominant  
TT  (220)   114.85±  2.24   0.137  
TG/GG  (528)   110.92±  1.48       
*TG  
Additive  
TT  (222)   67.84±  2.20   0.248  
TG  (367)   69.40±  1.74       
GG  (166)   70.71±  2.54       
Dominant  
TT  (222)   67.84±  2.20   0.329  
TG/GG  (533)   69.81±  1.46       
*   Cholesterol and TG values are log transformed. 
** HDL and LDL values are square root transformed. 
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4.0  DISCUSSION 
The APOC4 gene belongs to the apolipoprotein family, which plays an essential role in lipid 
metabolism, and is located within the APOE/C1/C4/C2 gene cluster on chromosome 19q13.2. 
ApoCIV is like ot???? ????????????????? ???? ???? ?-helical amphipathic structures that enable 
apolipoproteins binding to lipid molecules. The presence of apoCIV on VLDL and HDL 
lipoprotein particles strongly suggests its involvement in VLDL and HDL metabolisms.  
Although the exact function of apoCIV in lipid metabolism is not well known, 
overexpression of APOC4 in transgenic mice yields hypertrigylceridemic phenotype, suggesting 
its important role in TG metabolism. Meta analysis of Linkage studies on families with diverse 
ethnicity revealed a broad linkage peak on chromosome 19 (19p13-19q13.24) with different lipid 
traits, which suggest that complex genetic interaction among different genes in this linkage 
region might have direct impact on modulating lipid profile (Malhotra et al., 2007). Since 
APOC4 is part of the APOE/C1/C4/C2 gene cluster in the linked region on chromosome 19, 
genetic variations in the APOC4 gene alone or in conjunction with other candidate genes in the 
region might affect plasma lipid profile. 
Extensive genetic association studies have been performed on the other apolipoprotein 
genes in this gene cluster, especially on APOE. In order to fully evaluate the genetic role of these 
genes in lipid metabolism, it is important to examine all apolipoprotein genes in this gene cluster. 
To our knowledge, only one previous study from our group sequenced the coding and intron-
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exon boundaries of the APOC4 gene in randomly selected 50 NHWs individuals and identified 
five point mutations (Kamboh et al., 2000). However, since individuals were not selected with 
regards to their lipid profile and the entire gene was not sequenced, the previous study fell short 
of identifying all possible variants in the APOC4 gene. 
To our knowledge, this is the first study that aimed to resequence the entire APOC4 gene 
with its flanking sequence in selected individuals with extreme lipid profile in order to identify 
potential all common and rare variants in APOC4 that are associated with lipid level. 
 
4.1 COMPARISON OF OUR STUDY RESULTS WITH PUBLICLY AVAILABLE 
DATABASES 
We compared our results to publicly available databases (SeattleSNPs and CHIP). SeattleSNPs 
sequenced a total of 4,510 bp genomic region of APOC4, including 956 bp in the 5’flanking 
region and 297 bp in the 3’flanking region in 48 African Americans (24 from Jackson, 
Mississippi and 24 from Coreill,  New  Jersey), and 48 individuals of European Descent (24 from 
Rochester, Minnesota and 24 from North Karelia, Finland). All individuals were selected 
randomly irrespective of their lipid level. In this study, we sequenced a total of 5,083 bp genomic 
region of APOC4, including all exons and introns plus 956 bp in the 5’flanking region, and 876 
bp in the 3’flanking region in a total of 95 NHWs and 95 Blacks having extreme low and high 
HDL-C levels.  
We noticed difference in our results compared to publicly available databases 
(SeattleSNPs and CHIP), which are more likely due to our larger sample size, selection criteria 
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or our larger sequencing genomic region. Furthermore, we used African sample compared to 
African Americans used in SeattleSNPs that have considerable white admixture. For variants that 
were identified in our study but not reported in databases, could be due to our larger sample size 
and selection criteria. 
A total of 30 variants have been previously reported in publicly available databases 
(SeattleSNPs or CHIP) compared to a total of 65 variants identified in this study. In public 
databases (SeattleSNPs and CHIP) 15 variants have been reported in Europeans with 6 and 9 
variants having MAF<5%, and MAF ??????????????????????????????????????????????????????????
plus a dinucleotide microsatellite were identified in this study in NHWs with 13 variants having 
MAF<5%, and 13 variants having MAF ?? ???? ?? ?????? ??? ??? ????????? ????? ????? ????????? ???
databases in African American with 10 and 15 variants having MAF < 5%, and MAF ?? ????
respectively. By comparison, we found 51 variants plus a dinucleotide microsatellite in Blacks; 
30 variants were observed at MAF<5%, and 21 variants were observed at MAF ?????? ????????
all the reported common variants in African Americans and Europeans in our study, except 3 
reported rare variants in Europeans (2703G>T/ MAF=0.025, 2753G>A/ MAF=0.02, and 
3532A>G/ MAF=0.008) and 4 reported rare variants in African Americans, (2683G>A/ 
MAF=0.02, 2886T>C/ MAF=0.02, 3532A>G/ MAF=0.017, and 4346A>T/ MAF=0.02). We 
identified 39 new variants in this study, 14 of them were present in NHWs and 28 in African 
Blacks. 
Five variants affecting the coding region were reported in databases (3 non-synonymous, 
and 2 synonymous), including 3498C>T (Pro36Leu) in exon 2, 3502C>T (Ser37Ser) in exon 2, 
3546G>A (Gly52Asp) in exon 2, 3592C>T (Asp67Asp) in exon 2, and 3927T>G (Leu96Arg) in 
Exon 3. Of the coding variants, 3502C>T (Ser37Ser) and 3592C>T (Asp67Asp) were present in 
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African Americans only, 3546G>A (Gly52Asp) in European only, and 3498C>T (Pro36Leu) and 
3927T>G (Leu96Arg) in both populations. In this study, we identified all the 5 reported exonic 
variants plus two additional non-synonymous variants among African Blacks, including 
3969A>C (Lys110Tyr) in exon 3 and 4012G>A (Lys124Arg) in exon 3.  
Three main factors may explain our ability in identifying more variants in this study than 
in previous studies: 1) our sequencing sample size was larger, 2) individuals were selected based 
on their extreme low or high HDL-C levels, and 3) our larger sequencing genomic region. In 
comparison to public databases, 5 unique variants were identified in Europeans, and 15 unique 
variants in African Americans. We found 13 variants unique to NHWs, and 38 variants unique to 
Blacks. Similar to publicly available databases, we found more unique variants in Blacks than in 
NHWs. 
In our study, we found 4 indels (2 deletions, and 2 insertions), including 92_94del3, 
150_151ins114, 1325_1327del3, and 1430_1431ins1 in which the first three indels were present 
in both samples (NHW and African Black), and the last insertion was present only in Blacks. By 
comparison, the databases reported only one deletion (92_94del3), which was common in both 
European and African American populations. The largest insertion, 150_151ins114 was LINE-1 
(long interspersed nuclear element-1), which was in complete LD with previously reported 
92_94del3. Another variant, 108G>A, in addition to 150_151ins114 was in strong LD with 
92_94del3 and both of them were not reported in databases.  
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4.2 DISTRIBUTION OF APOC4 VARIANTS IN HIGH AND LOW HDL- 
CHOLESTEROL GROUPS 
The distribution of unique rare or less common variants (MAF<5%) was similar in both samples 
(NHW and African Black) in which more unique rare variants were present in the low HDL-C 
group than in the high HDL-C group (8 vs. 2 in NHWs and 10 vs. 7 in African Blacks). 
Accumulation of rare variants in the low HDL-C group more likely has damaging effect (Cohen 
et al., 2004). Although the distribution of unique rare variants in low and high HDL-C groups 
was similar in both NHW and Black samples, the percentage of individuals with rare or less 
common variants in the low HDL-C group was higher in NHWs and lower in Blacks compared 
to the high HDL-C group. 
In NHWs, 31.3% of individuals in the low HDL-C group (15/48) had rare or less 
common variants versus 10.6% in the high HDL-C group (5/47). In NHWs, rare variants could 
have a protective feature against fatal illness that enable individuals with extremely low HDL-C 
survive. Conversely, in Blacks we observed more individuals with rare or less common variants 
in the high HDL-C group (26/48) than in the low HDL-C group (22/47) (54% vs. 46%). The 
difference in the rare or less common variants distribution among NHWs and Blacks could 
explain the variation in HDL-C level in which Blacks have higher HDL-C level than Whites 
(American Heart Association, 2002). Furthermore, different LD pattern in both samples (NHW 
and African Black) could explain the variation in rare or less common variants distribution 
among low and high HDL-C groups in NHWs and African Blacks. 
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4.3 COMPARISON OF OUR STUDY RESULTS WITH PUBLISHED LITERATURE 
One recent prospective study was conducted to test the association between common variants 
within APOE/C1/C4/C2 gene cluster and lipid traits (Ken-Dror et al., 2010). A total of 9 
common SNPs within this cluster, including APOE/ rs405509, APOE/ rs439401, APOC1/ 
rs4420638, APOC1/ rs4800770, APOC1/ rs7259004, APOC4/ rs12691089, APOC4/ rs5167, 
APOC2/ rs5127, APOC2/ rs10413089 were genotyped in 2,767 middle-aged men from the 
Second Northwick Park Heart Study (NPHSII). Only two APOC4 common exonic SNPs were 
included in the genotyped SNPs; rs12691089 (Gly52Asp) in exon 2, and rs5167 (Leu96Arg) in 
exon 3. rs5167 was strongly associated with high HDL-C and apoAI levels  (p<0.001), and LDL-
C (p= 0.03) (Ken-Dror et al., 2010).  
By comparison, we did not observe striking association with HDL-C or LDL-C in NHWs 
but a borderline association was observed with LDL-C (p=0.127). Similarly, a borderline 
association was observed between rs5167 and LDL-C (p=0.061) in Blacks. Although we did not 
find an association between this variant and HDL-C in NHWs and Blacks (p=0.770 and 0.532, 
respectively), in the sequencing analysis the minor allele frequency was higher in the high HDL-
C group than in the low HDL-C group in both NHWs and African Blacks (0.372 vs. 0.309 in 
NHWs and 0.554 vs. 0.500 in Blacks), which was consistent with the previous results. Our small 
sample size might explain our inability in detecting the small effect size of some common 
variants or the modest effect size of some rare variants. Although there was no significant 
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association between rs12691089 (Gly52Asp) and HDL-C levels in Ken-Dror et al. (2010), we 
observed this SNP in the low HDL-C group only in NHWs in this study.  
Previously, Kamboh et al. (2000) reported association of APOC4 exonic variants: 
3498T>C/ rs1132899 (Pro36Leu) and 3927T>G/ rs5167 (Leu96Arg) and high TG level in NHW 
women (p=0.03 and 0.08, respectively). Another association was found in men between 979G>A 
and HDL-C (p=0.06) (Kamboh et al., 2000). Although we did not find statistically significant 
association between these genetic variants, we observed a trend of association of 3498T>C 
(rs1132899) and 3927T>G (rs5167) and TG in NHWs which was consistent with the previous 
findings. Although we used the same NHW population with similar sample size (n=623 in this 
study vs. n=592 in Kamboh et al. (2000)), we did not observe significant association of 
rs1132899 and rs5167 with TG. One of the factors that might explain our limitation in detecting 
the reported associations is our association analysis method. Due to gender-specific effect, we 
did not expect to find this association in the entire sample since Joint gender analysis was 
performed in this study. So, stratifying based on gender could be more powerful in detecting 
gender-specific effect. 
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4.4 CONCLUSIONS AND FURTHER DIRECTIONS 
Coronary heart disease continues to be a leading cause of premature mortality and co-morbidity 
in western countries and dyslipidemia with high LDL-C and low HDL-C as major risk factors for 
CHD. Little attention has been paid to the role of APOC4 genetic variants in relation to plasma 
lipid levels, although it is an important biological and positional candidate gene that is part of the 
APOE/C1/C4/C2 gene cluster on chromosome 19q13.2. Even though there is no known major 
role of apoCIV in HDL metabolism, this study was undertaken to catalogue APOC4 common 
and rare variants and to assess their effects on lipid traits.  
Our findings were consistent with previous results. For the reported associations, even 
though we did not obtain statistically significant associations, which could be due to our small 
sequencing sample size, we did observe trend in the corresponding lipid trait in the same 
direction. We observed borderline associations in some variants with different lipid traits that 
were unreported previously and need to be confirmed by genotyping in the total samples. More 
unique rare variants were observed in the low HDL-C group than the high HDL-C group in both 
samples (NHWs and Blacks). Further studies in larger sample size are warranted in order to 
confirm the previously reported association signals and borderline association observed in this 
study. Furthermore, it is important to examine the distribution of unique rare variants in the total 
sample, and to detect more rare variants with modest effect size or common variants with small 
effect size. Since APOC4 is part of the APOE/C1/C4/C2 gene cluster, a joint analysis of all these 
genes would provide more information about their role in lipid metabolism. 
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